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2. Summary 
The microbiota in the gastrointestinal tract influence immune homeostasis. 
Many microbes have different effects on the immune system. Enterogenic pathogens 
induce strong inflammatory responses within the gastrointestinal tract, while commensal 
bacteria induce tolerance. One of the intestinal tolerogenic bacteria is Bifidobacterium 
infantis 35624 (B. infantis), which has been previously shown to protect against 
inflammatory diseases in murine models, such as colitis and respiratory allergy.  The 
protective host immune response was demonstrated to include the induction of 
T regulatory cells. However, the molecular basis for this effect was not well understood. 
 
In this thesis the molecular mechanism responsible for B. infantis recognition by 
human monocyte-derived dendritic cells (MDDCs), myeloid dendritic cells (mDCs) and 
plasmacytoid dendritic cells (pDCs) was investigated. Moreover, the influence of 
dendritic cell (DC) subsets on naïve T cell polarization was assessed. B. infantis 
stimulated MDDCs, mDCs and pDCs secreted interleukin (IL)-10 with low levels of IL-
12p70 and expressed indoleamine 2,3-dioxygenase (IDO). This microbe did not induce 
interferon (IFN)-α in pDCs. MDDCs and mDCs IL-10 secretion was Toll-like receptor 
(TLR)2/6 dependent, while pDCs IL-10 secretion was TLR9 dependent. Moreover, 
MDDCs and mDCs expressed retinaldehyde dehydrogenase 2 (RALDH2) in response to 
B. infantis. RALDH2 expression was TLR2 and DC-SIGN dependent. Co-culture of 
naïve T cells with bacteria primed DC subsets resulted in enhanced expression of Foxp3 
in CD4+CD25+ cells. Foxp3+ T cell induction by MDDC and mDC required TLR2, 
DC-SIGN and retinoic acid, while for pDCs IDO was required. Enhanced expression of 
Foxp3 in T lymphocytes was also observed in peripheral blood of healthy volunteers, 
who received  B. infantis for 8 weeks. Moreover, these T regulatory (Treg) cells 
displayed strong regulatory phenotype, including inducible T-cell costimulator (ICOS) 
and cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression.  
 
As B. infantis enhanced RALDH2 expression and retinoic acid production by 
MDDCs and mDCs, the importance of this metabolite was further examined in animal 
models. Retinoic acid metabolizm by mucosal CD103+ DCs after B. infantis exposure 
was confirmed and the role of B. infantis- induced retinoic acid metabolism in 
protection against dextran sodium sulphate (DSS)-induced colitis was analyzed. 
Summary 
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B. infantis feeding led to increased number of CD103+RALDH+ DCs in the small 
intestinal lamina propria (LP) of healthy mice. Foxp3+ Treg cells were also elevated in 
LP, while T helper (Th)1 and Th17 subsets were decreased. Citral (RALDH enzyme 
inhibitor) treatment blocked the increase in CD103+RALDH+ DCs and the decrease in 
Th1 and Th17 subsets. There was no citral effect on the Foxp3+ Treg cell population, 
which suggests that other immunoregulatory factors may play a role. B. infantis reduced 
the severity of DSS-induced colitis. This effect was associated with decreased Th1 and 
Th17 cells in LP. Moreover, in the colon there was less neutrophil infiltration, measured 
using myeloperoxidase activity. Citral treatment confirmed that these effects were 
related to retinoic acid metabolism. CD11b+CD103+ DCs increased and RALDH+ DCs 
decreased in LP of control colitic mice. In contrast, numbers of RALDH+ DCs in LP of 
B.  infantis-fed animals were maintained. 
 
In this thesis two different mechanisms of Foxp3+ T cells induction by 
B. infantis activated DCs are presented: (1) TLR2, DC-SIGN and retinoic acid-
dependent Treg induction by mDCs; (2) IDO-dependent Treg induction by pDCs. 
RALDH2 upregulation and retinoic acid involvement were specific for this microbe. 
Two related Bifidobacteria strains B. animalis and B. globosum were not able to induce 
retinoic acid metabolism in DCs, suggesting that not all microbes have the same 
immunomodulatory properties.  Thus, CD103+  small intestine LP DCs producing 
retinoic acid are a potential cellular target for microbiota-mediated effects on mucosal 
immunoregulation and homeostasis. Cross-talk between many pattern recognition 
receptors and metabolic pathways determines the response to B. infantis. RALDH2 
expression and retinoic acid production link nutrition (vitamin A), commensal 
microbiota and tolerance induction. These results suggest that supplementation with 
specific tolerogenic microbes may provide benefits to patients suffering from wide 
range of mucosal inflammatory disorders. 
 
 
 
 
 
Zusammenfassung 
 
4 
 
3. Zusammenfassung 
Die mikrobielle Besiedelung des Magen-Darm-Trakts hat einen Einfluss auf die 
Homöostase des Immunsystems. Nicht alle Mikroben haben denselben Effekt. So 
verursachen enterogene Pathogene eine starke Entzündungsantwort im Gegensatz zu 
kommensalen Bakterien, die Toleranz induzieren. Bifidobacterium infantis 35624 
(B. infantis) ist so ein toleranzinduzierendes Darmbakterium, von dem schon bekannt 
war, dass es in Mausmodellen eine schützende Wirkung gegen die Entstehung von 
Entzündungskrankheiten wie Kolitis und Atemwegsallergien hat. Diese schützende 
Wirkung wurde der Aktivierung von regulatorischen T Zellen zugeschrieben. 
Nichtsdestotrotz sind die molekularen Grundlagen für diesen Effekt bislang nicht 
ausreichend verstanden. 
In der vorliegenden Arbeit wurde der molekulare Mechanismus untersucht, wie 
B. infantis von humanen aus Monozyten differenzierten dendritischen Zellen (MDDC), 
myeloiden dendritischen Zellen (mDC) und plasmazytoide dentritische Zellen (pDC) 
erkannt wird. Zusätzlich wurde der Einfluss der dendritischen Zellsubtypen auf die 
Polarisierung naiver T Zellen untersucht. Wir fanden, dass mit B. infantis stimulierte 
MDDCs, mDCs und pDCs Interleukine (IL)-10 und ein wenig IL-12p70 sezernieren, 
zusätzlich exprimieren sie die Indoleamin 2,3-dioxygenase (IDO). Die Expression von 
Interferon (IFN)-α in pDCs wurde nicht beeinflusst. Die IL-10 Sekretion von MDDCs 
und mDCs ist abhängig von TLR2/TLR6 während diejenige von pDCs von TLR9 
abhängig ist. Dann exprimierten MDDCs und mDCs RALDH2 als Antwort auf 
B. infanits Stimulation. Diese Expression war abhängig von TLR2 und DC-SIGN. Ko-
Kulturen von naiven T Zellen mit dendritischen Zellen, welche mit den Bakterien 
voraktiviert wurden, erhöhten die Expression von Foxp3 in CD4+CD25+ Zellen. Die 
Induktion von Foxp3+ T Zellen mit MDDCs und mDCs benötigte TLR2, DC-SIGN und 
Retinolsäure, während bei pDCs IDO nötig war. Eine Erhöhung der Foxp3 Expression 
in T Lymphozyten wurde ausserdem in peripherem Blut von gesunden Freiwilligen 
gefunden, welche B. infantis während 8 Wochen konsumiert hatten. Der regulatorische 
Phänotyp dieser Zellen wurde durch die Expression vom induzierbarem T Zell Ko-
Stimulator (ICOS) und vom Zytotoxischen T Lymphozyten Antigen 4 (CTLA-4) 
unterstrichen. 
Weil B. infantis die RALDH2 Expression und somit die Retinolsäureproduktion 
in MDDCs und mDCs erhöht, untersuchten wir die Wichtigkeit dieses Prozesses in 
Zusammenfassung 
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Tiermodellen. So konnten wir die Retinolsäuremetabolisierung in CD103+ 
dendritischen Zellen der Schleimhaut nach Exposition gegenüber B. infantis bestätigen. 
Zusätzlich haben wir die Rolle der Retinolsäuremetabolisierung nach B. infantis 
Kontakt in einem Dextran Natriumsulfat (DSS)-induzierten Kolitismodell in Mäusen 
analysiert. Fütterung von B. infantis führte zu höheren Zahlen an CD103+RALDH+ 
dendritischen Zellen in den Lamina Propria (LP) Zellen des Dünndarms von gesunden 
Mäusen. Zusätzlich waren die Foxp3+ regulatorischen T Zellen erhöht in LP, während 
TH1 und TH17 Subtypen reduziert waren. Zusätzliche Behandlung der Mäuse mit Citral 
(ein RALDH Enzym Inhibitor) inhibierte die Erhöhung von CD103+RALDH+ 
dendritischen Zellen, die Reduktion der TH1 und TH17 Subtypen blieb aber bestehen. 
Wir beobachteten auch keinen Citral Effekt auf die Foxp3+ regulatorischen 
T Zellpopulation, woraus wir schliessen, dass zusätzlich andere immuno-regulatorische 
Faktoren eine Rolle spielen könnten. Dann reduzierte B. infantis die Symptome der 
DSS-induzierten Kolitis. Dieser Effekt war assoziiert mit weniger TH1 und TH17 
Zellen in LPs. Zusätzlich war der Darm weniger von Neutrophilen Zellen infiltriert, was 
durch Messung der Myeloperoxidase Aktivität bestimmt wurde. Die Behandlung der 
Mäuse mit Citral bestätigte, dass diese Effekte im Zusammenhang mit der 
Retinolsäuremetabolisierung stehen. In den LP von unbehandelten Mäusen, die an 
Kolitis erkrankt waren, fanden wir mehr CD11b+CD103+ dendritische Zellen während 
die RALDH+ dendritischen Zellen reduziert waren. Im Gegensatz dazu waren die 
RALDH+ dendritischen Zellen durch die B. infantis Fütterung erhöht. 
In der vorliegenden Arbeit stellen wir zwei verschiedene Mechanismen zur 
Foxp3+ T Zell Induktion vor: (1) mDCs, welche regulatorische T Zellen in 
Abhängigkeit von TLR2, DC-SIGN und Retinolsäure induzieren; (2) pDCs, welche 
regulatorische T Zellen IDO-abhängig induzieren. Die RALDH2 Hoch-Regulierung und 
die Retinolsäure Produktion ist spezifisch für B. infantis. Zwei Verwandte 
Bifidobakterienstämme B.animalis und B.globosum führten nicht zur 
Retinolsäuremetabolisierung in dendritischen Zellen. CD103+ dendritische Zellen der 
LPs des Dünndarms, welche Redinolsäure produzieren, wurden schon als potenzielles 
Ziel des Mikrobiota-vermittelten Effekts auf die Immunregulation und Homeostase der 
Schleimhäute beschrieben. Das Zusammenspiel verschiedener 
Mustererkennungsrezeptoren und metabolischer Wirkungswege bestimmt die Wirkung 
von B. infantis. Die Expression von RALDH2 und die Retinolsäureproduktion 
verbinden die Ernährung (Vitamin A), die Darmflora und die Toleranzinduktion des 
Zusammenfassung 
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Immunsystems. Unsere Resultate zeigen auf, dass die Ergänzung der Nahrung mit 
toleranzinduzierenden Mikroben Patienten mit Entzündungskrankheiten der 
Schleimhäute helfen könnte. 
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4. Abbreviations 
ADH aldehyde dehydrogenase 
AIEC adherent-invasive E. coli 
APC antigen presenting cell 
ASC antigen specific cell 
B. infantis Bifidobacterium infantis 35624 
BmDC bone marrow-derived dendritic cell 
cAMP cyclic adenosine monophosphate 
CARD caspase recruitment domain 
CBP CREB-binding protein 
CCL CC chemokine ligand 
CCR9 CC chemokine receptor 9 
CFSE carboxyfluorescein succinimidyl ester 
CLA conjugated linoleic acid 
CLR C-type lectin receptor 
CRABP cellular retinoic acid binding protein 
CRD carbohydrate recognition domain 
CREB cAMP response element-binding protein 
CRP C reactive protein 
CTLA-4 cytotoxic T-lymphocyte antigen 4 
CX3CR1  CX3C chemokine receptor 1 
DAMP danger-associated molecular pattern 
DC dendritic cell 
DCAR dendritic cell immunoactivating receptor 
DCIR DC immunoreceptor 
DC-SIGN dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin 
DSS dextran sodium sulphate 
ER endoplasmatic reticulum 
ERK extracellular signal-regulated kinases 
FABP5 fatty acid binding protein 5 
Foxp3 forkhead box P3 
GABA γ-amino butyric acid 
Abbreviations 
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GALT gut-associated lymphoid tissue 
GM-CSF granulocyte macrophage colony-stimulating factor 
GPCR G protein coupled receptor 
IBD Inflammatory Bowel Disease 
ICER inducible cAMP early repressor 
ICOS inducible T-cell costimulator 
IDO indoleamine-2,3-dioxygenase 
IFN interferon 
Ig immunoglobulin 
IKK IκB kinase 
IL interleukin 
iNOS inducible nitric oxide synthase 
IPS-1 interferon promoter-stimulating factor 1 
IRAK IL-1 receptor-associated kinase 
IRF IFN-regulatory factor 
iTreg inducible T regulatory cell 
JNK c-Jun N-terminal kinase 
LAG3 lymphocyte-activation gene 3 
LBP LPS-binding protein 
LCFA long-chain fatty acid 
LN lymph node 
LP lamina propria 
LPS lipopolysaccharide 
LTA lipoteichoic acid 
MAdCAM mucosal addressin cellular adhesion molecule 
MAPK mitogen-activated protein kinase 
MDA5 melanoma differentiation-associated gene 5 
mDC myeloid dendritic cell 
MDDC monocyte-derived dendritic cell 
MDP muramyl dipeptide 
MGL macrophage galactose-type lectin 
MHC major histocompatibility complex 
MLN mesenteric lymph node 
MyD88 myeloid differentiation primary response protein 88 
Abbreviations 
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NLR NOD-like receptor 
NLRC nuclear oligomerization domain proteins subfamily C 
NOD nonobese diabetic mice 
NOD1 nucleotide-binding oligomerization domain 1 
NOD2 nucleotide-binding oligomerization domain 2 
PAMP pathogen associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
pDC plasmacytoid dendritic cell 
PGE2 prostaglandin E2 
PLN peripheral lymph node 
PP Peyer’s patch 
PPAR peroxisome proliferator-activated receptor 
PRR pattern recognition receptor 
PSA polysaccharide A 
PTGN peptidoglycan 
RALDH retinaldehyde dehydrogenase 
RAR retinoic acid receptor 
RARE retinoic acid response element 
RBP retinol-binding protein 
RDH10 retinol dehydrogenase 10 
RIG-I retinoic acid inducible gene I 
RIP1 receptor-interacting protein 1 
RLR RIG-I-like receptor 
RXR retinoid X receptor 
SCFA short-chain fatty acid 
SDR short chain dehydrogenase reductase 
SHP-1 Src homology phosphatase-1 
siRNA small interfering RNA 
SNP single nucleotide polymorphism 
SOCS3 suppressor of cytokine signaling 3 
STAT6 signal transducer and activator of transcription 6 
TAK1 TGF-β-activated kinase 1 
TGF-β transforming growth factor beta 
Th T helper 
Abbreviations 
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TIR Toll-interleukin 1 (IL-1) receptor 
TIRAP TIR domain containing adaptor protein 
TLR Toll-like receptor 
TNF tumor necrosis factor 
TRADD TNF receptor type 1-associated DEATH domain protein 
TRAF TNF receptor-associated factor 
TRAM TRIF-related adaptor molecule 
Treg T regulatory cell 
TRIF TIR-domain-containing adapter-inducing interferon-β 
TTR transthyretin 
VAD vitamin A deficient mice 
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5. Introduction 
 
5.1 Human gut microbiota 
 
Our epithelial surfaces are colonized not only by numerous bacteria species, but 
a diverse microbial community, which consists of bacteria, archea, fungi, protozoa and 
viruses (1-5). Recent developments in high-throughput sequencing have uncovered 
a higher diversity in human microbiota than expected (6, 7). It was demonstrated that 
the microbiota encode at least 100-fold more specific genes than found within the 
human genome (8), which raises the question as to how big an impact they can have on 
the human host. 
 
Greater than 1014 bacteria colonize the mucosal surfaces of the body. Especially 
rich in bacteria is the lower gastrointestinal tract. It harbors trillions of beneficial 
commensal bacteria, numbering at least 1000-5000 species (9). Most of them are from 
the phyla Bacteroidetes or Firmicutes, whereas Actinobacteria, Proteobacteria, 
Verrucomicrobia, Cyanobacteria, Fusobacteria are represented at lower levels (10-12). 
Moreover, the human gut is colonized by methanogens, which belong to Archea (13). 
Microbiota distribution throughout the gastrointestinal tract depends on many factors 
such as host-microbial, microbial-microbial interactions and nutrients accessibility. In 
healthy individuals, Proteobacteria spp (mainly Enterobacteria), Lactobacillales and 
Erysipelotrichales (especially Turicibacter spp) dominate in the small intestine. The 
large intestine is colonized mainly by Bacteroidetes and Clostridia (Figure 1) (14).  
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Figure 1. Dominant bacterial groups within the gastrointestinal tract. (Reproduced from 
Kamada N, Nat Immunol 2013) Small intestine, rich in easily accessible nutrients, is colonized by 
Proteobacteria, Lactobacillales and Erysipelotrichales (15). In contrast,  large intestine contains 
undigestible nutrients, which facilitates growth of diverse Bacteroidales and Clostridiales.  
 
These differences are strongly related to nutrient distribution. The small intestine 
is rich in monosaccharides, disaccharides and amino acids used by host and microbes, 
while the large intestine containes host-indigestible fibers. Small intestinal bacteria, 
such as Proteobacteria, cannot digest polysaccharides and cannot use them as an energy 
source. In contrast colon bacteria, such as Bacteroidetes, possess the ability to scavenge 
polysaccharides (14). Nevertheless, this feature can be highly diverse even for bacteria 
from the same phyla and partially explains why the colon is the most diverse in bacteria 
species within the gut. Some bacteria, such as methanogens, do not use sugars as an 
energy source, instead they obtain energy from hydrogen molecules, which are a side 
product of obligate anaerobic metabolism (13). The intestinal environment is also rich 
in ecological networks, which allows some commensals to acquire critical nutrients 
from their intestinal neighbors. For example, Eubacterium dolichum and Lactobacillus 
johnsonii cannot synthetize certain amino acids and need to incorporate them from the 
intestinal environment (16, 17). Changes in any of these components lead to alteration 
in the entire system, which was demonstrated following antibiotic use and diets based 
on fat and protein or vegetable fiber components. 
 
Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology,  Kamada N, et al. Control of pathogens 
and pathobionts by the gut microbiota. 14:685-90, copyright 2013. 
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There is no doubt that diet impacts intestinal microbiota composition from early 
life. The breast feeding of infants favors colonization by more Bifidobacteria species 
compared to formula fed infants (18, 19). Recently, association between diet and gut 
microbiota was investigated in human adults. Existence of three gut microbiota groups, 
called enterotypes, was proposed (20). They were dominated by Bacteroides, Prevotella 
and Ruminococcus. A diet high in fat and animal protein with low carbohydrate intake 
resulted in high levels of Bacteroides and low level of Prevotella. In contrast, diets high 
in simple carbohydrates  and low in fat and animal protein showed an inverted pattern 
with low Bacteroides and high Prevotella. These results were observed only with long-
term dietary habits. In the case of short-term diet changes, the gut microbiota has the 
ability to respond within 24hours, although it does not lead to an enterotype switch (21).  
 
The microbiota in the gut lumen is continuously monitored by the gut-associated 
lymphoid tissue (GALT) (Figure 2). The monolayer of intestinal epithelial cells 
(enterocytes) forms a barrier between the luminal microbiome and lamina propria (LP) 
cells. It is worth to mention that bacteria can be already recognized by a limited number 
of receptors expressed on enterocyte surface. However, microbes are mainly sampled by 
LP dendritic cells (DCs) reaching their dendrites into the gut lumen, between tight 
junctions on enterocytes. Alternatively, microbes can be delivered to Peyer’s patches 
(PP) through M cells, which are specialized epithelial cells in the intestinal epithelial 
cell lining. Subsequently, microbes are recognized and taken up by PP resident DCs. 
Bacterial components are recognized via diverse pattern recognition receptors (PRRs), 
which are present on the surface, in the intracellular compartments and in the cytoplasm 
of DCs. Moreover, DCs respond to microbial metabolites produced in the gut lumen 
during fermentation processes. Bacterial activated DCs secrete diverse cytokines, 
immunomodulatory factors and  interact with T and B lymphocytes, which leads to pro- 
or anti-inflammatory adaptive responses. Antigen presentation takes place locally in LP 
and after DC migration to the mesenteric lymph node (MLN). In addition, some DCs 
can stay within PP and there prime naïve T cells (22). 
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Figure 2. Monitoring of microbiome in the gut lumen by intestinal immune system. 
(Reproduced from Besselink MG, Dig Sur 2005) Dendritic cells in the LP and PP recognize and  take up 
bacteria from the gut lumen. Subsequently, they present antigens locally in LP and after migration to 
MLN (23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CREDIT: Taina Litwak 
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5.2 Tolerogenic microbes 
 
Many microbes have different effects on the immune system. Enterogenic 
pathogens induce strong inflammatory responses within gastrointestinal tract, while 
commensal bacteria can induce tolerance. During the last years many groups 
demonstrated that microbiota manipulation can alter cytokine patterns and decrease 
inflammatory symptoms in colitis and arthritis models. One previously described 
tolerogenic commensal bacterium is Bifidobacterium infantis 35624 (B. infantis). We 
focused on this microbe, which was shown to reduce inflammation in murine models 
and in human studies, but the molecular mechanism of this effect was unknown. 
 
 B. infantis was isolated from resected healthy human gastrointestinal tissue 
more than decade ago and has been extensively studied for its potential 
immunoregulatory effects on human cells, such as epithelial cells, DCs and 
T lymphocytes. For better understanding of its anti-inflammatory properties murine 
models were used and human trials were conducted. 
 
Epithelial cells create a monolayer, which separates the gut lumen and LP cells. 
B. infantis was shown to adhere to epithelium but it induced neither NF-κB activation 
nor chemokine secretion (24). Moreover, secretion of CC chemokine ligand (CCL)-20 
and interleukin (IL)-8 after stimulation with pathogens or Toll-like receptor (TLR) 
ligands was reduced in the presence of B. infantis (24, 25). These results suggest, that 
this bacterium can act on epithelial cells, which express limited number of PRRs, 
inducing anti-inflammatory responses after first contact with gut cells.  
 
The second group of cells, which respond to B. infantis are DCs. They are 
effective in sampling the gut lumen by use of dendrites and after activation some of 
them migrate from LP to MLN. DCs were isolated from human MLN from 
Inflammatory Bowel Disease (IBD) patients undergoing surgical resection of the 
inflamed gut. After stimulation with B. infantis they secreted IL-10 and TBF-β, while 
no IL-12 and tumor necrosis factor (TNF)-α were detected (26). However, these DCs 
were able to produce both pro-inflammatory cytokines: IL-12 and TNF-α in response to 
pathogenic bacterium Salmonella typhimurium. In contrast, DCs from peripheral blood 
secreted TNF-α after stimulation with both bacteria, whereas IL-12 was not induced in 
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both peripheral blood and mucosal DCs. This suggests that the response to commensal 
bacteria is more specific for intestinal DCs than for non-gut DCs.  
 
As activated DCs can influence further adaptive responses, B. infantis effect on 
tolerogenic T lymphocyte subset was elucidated. Forkhead box P3 (Foxp3) T regulatory 
(Treg) cells were increased after bacterial administartion in murine models. Moreover, 
these cells were functional and protected against pathogen or lipopolysaccharide (LPS) 
induced NF-κB activation (27). Nevertheless, induction of  Treg cells seems to be not 
equally specific and effective for all commensal microbes. Other bacteria, such as 
Bifidobacterium breve AH1205 and Lactobacillus salivarius AH102 did not induce 
Treg cells and did not protect against allergic airway inflammation (28). 
 
B. infantis immunoregulatory properties, including Treg induction were tested in 
numerous murine models of inflammatory diseases. This bacterium was analyzed in 
infection models, such as  Salmonella typhimurium infection. Characteristic strong 
inflammation, including NF-κB activation, pro-inflammatory cytokines secretion and 
tissue damage were attenuated by B. infantis in Treg dependent manner (27).  Moreover, 
this microbe reduced severity of diverse colitis models, including the IL-10-/-, the SCID 
lymphocyte adoptive transfer and the dextran sodium sulphate (DSS) model (20, 30). 
Interestingly, B. infantis did not loose anti-inflammatory properties in IL-10 deficient 
mice suggesting that other immunomodulatory molecules secreted by DCs have to play 
an important role.  
 
Tolerogenic properties of B. infantis  were also analyzed in humans. Patients 
with Irritable Bowel Syndrome improved after bacterial consumption (31, 32), 
confirming results obtained in mice. However, in these studies non-gut related markers 
were not tested. Recently, the role for specific bacterial strains in orchestrating general 
tolerance mechanisms was shown. B. infantis feeding decreased inflammatory markers 
in ulcerative colitis and other non-intestine disorders, such as chronic fatigue syndrome 
and psoriasis (33).  
 
All these results have suggested the strong immunoregulatory properties of 
B. infantis. However, the molecular mechanism leading to an anti-inflammatory 
cytokine secretion and increase in Tregs was not well understood. A better description 
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of tolerogenic mechanisms induced by B. infantis may result in diverse opportunities in 
creating commensal bacteria-based therapies for inflammatory disorders treatment and 
prevention. 
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5.3 Microbial metabolites in the gut 
 
The gut microbiota is recognized by receptors expressed on gastrointestinal cells 
and affects the balance between inflammation and tolerance. However, microbes are 
involved in many other processes taking place in the gut, including production of certain 
metabolites. The role of the microbiota in digestion, nutrient absorption and production 
is quite well characterized. Some commensal bacteria in the gastrointestinal tract are an 
important source of B and K vitamins and vitamins can act on immune system cells 
(34). Recently, it was discovered that immune cells can recognize vitamin intermediates 
produced by bacteria. The monomorphic major histocompatibility complex class-I 
related protein (MR1) is capable to present intermediate products of riboflavin 
biosynthesis pathway to mucosa-associated invariant T cells (35). Moreover, 
commensals contribute to regulation of bile acids, which are cholesterol-derived 
amphipathic molecules solubilizing fat in the small intestine. This process helps to 
digest, absorb fat and A, D, E, K vitamins. Commensal bacteria convert primary bile 
acids into secondary acids through dehydration reactions (36) and deconjugate bile 
acids promoting their elimination.  
 
Some metabolites produced by microbes in the gut can act on immune cells in 
a direct or indirect manner. However, this emerging area is still not deeply investigated 
and there is increasing evidence showing bacterial metabolites and nutrients impact on 
innate and adaptive responses. One of the most investigated bacterial metabolites are 
Short chain fatty acids (SCFAs), which consist of 1-6 carbons and are produced by 
commensal microbes in the colon from nondigestible plant-derived polysaccharides. 
Bacteroidetes are major producers of SCFA. Three SCFA are present in human 
intestinal lumen: butyrate, propionate and acetate (37). Butyrate inhibits histone 
deacetylases and NF-κB activation (38). Moreover, it serves as a main energy source for 
colonocytes, influencing the epithelial barrier. Treatment of human peripheral blood 
cells (PBMCs) with SCFAs decreased monocyte chemotactic protein-1 expression and 
TNF, interferon (IFN)-γ and IL-10 secretion in response to LPS (39). Butyrate action on 
DCs diminish their ability to present antigens as major histocompatibility complex II 
(MHCII), CD80, CD86 and CD40 are downregulated (40, 41). Moreover, DCs treated 
with butyrate decrease expression of IL-12 and increase IL-10 and IL-23 secretion (40, 
41). In co-cultures with T cells both IL-10 and IL-17 production is increased (40). 
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SCFAs act directly on T lymphocytes causing apoptosis and inhibition of proliferation 
(42, 43). Cytokine production by non-immune cells is also affected by butyrate. Caco-2 
cells produce less IL-8 in response to IL-1β and butyrate than IL-1β alone (44). In 
humans, IBD patients treatment with butyrate  reduced intestinal inflammation (45) and 
biopsies from lesions responded to butyrate treatment with inhibition of NF-κB 
activation and lower pro-inflammatory cytokine secretion (46). 
 
GPR43 is a G protein-coupled receptor (GPCR), which recognizes SCFAs, such 
as propionate and acetate. This receptor is expressed on neutrophils, eosinophils, 
activated macrophages and innate immune cells. The KxB/N serum-induced arthritis, 
allergic airway inflammation and murine model of IBD are exacerbated  in GPR43- 
deficient mice (Ffar2-/-) (47). Germ-free mice represent a similar phenotype and have 
very low levels of SCFA (47). Propionate and acetate promote neutrophil chemotaxsis 
through GPR43 (47). This response is due to an increase in intracellular calcium, 
decrease in cyclic adenosine monophosphate (cAMP) level and extracellular signal-
regulated kinases (ERK)1/2 activation (48). Moreover, Ffar2-/- mice had lower 
neutrophil infiltration in the colon than wild-type animals in DSS-induced colitis model 
(49). Another GPCR binding SCFA is GPR41, however its expression is low in 
neutrophils and monocytes (48, 50), suggesting a limited role in immune system 
regulation. 
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5.4 Microbiota alteration in diseases 
 
The role for the microbiota in influencing human health is better understood 
with every year. It does not only impact the digestive tract but also influences immune 
responses and metabolism. There is growing evidence suggesting that the gut 
microbiota contributes to metabolic disorders and pathogenesis of diverse diseases. 
However, only few examples are discussed in this introduction. It remains unknown 
whether microbiota alterations are a cause or a consequence of these diseases.  
 
5.4.1 Obesity, metabolic syndrome and diabetes 
 
Metabolic syndrome has become one of the most common diseases in developed 
countries. It consists of obesity, glucose homeostasis disorders (such as type 2 diabetes), 
lipid homeostasis disorders and hypertension (50). The gut microbiota has been shown 
to influence the amount of energy harvested from food and fat storage (51), 
subsequently leading to changes in host metabolism and energy balance (51-54). In 
obesity and type 2 diabetes, the microbiota can also contribute to development of low-
grade inflammation (55-57). This type of inflammation is common in obesity and type 
2 diabetes but is not included in the standard definition of metabolic syndrome. 
 
Firstly, gut microbiota changes were analyzed in genetically obese mice. The 
outcome was  an increase in Firmicutes and decrease in Bacteroides (52, 58). Moreover, 
a high-fat diet also reduced Bifidobacteria, Eubacterium rectale, Blautia coccoides and 
Bacteroides-like bacteria levels in murine intestine (55). Many other studies confirmed 
the Firmicutes increase and Bacteroides decrease associated with obesity in murine 
models (53, 59, 60).   
In humans, Firmicutes/Bacteroides ratio changes connected with obesity are not 
so clear (61-65), while more specific differences in gender or species were detected. 
Bifidobacterium abundance is lower in obese or type 2 diabetic patients than in healthy, 
lean individuals (63, 64) and Faecalibacterium prausnitzii is decreased in type 
2 diabetes (66).  
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5.4.2 Ulcerative colitis and Crohn’s disease  
 
IBD can be divided into two groups: ulcerative colitis, which is associated with 
T helper (Th)2 cytokines and NK-T cells (67, 68) and Crohn’s disease, which is 
associated with Th1 and Th17 responses. Ulcerative colitis affects the mucosal layer of 
the colon and inflammation is strongly diffuse, while Crohn’s disease is more 
heterogenous. It is characterized by diverse inflammatory lesions, which can be detected 
in any part of gastrointestinal tract. Lesions can differ in phenotype e.g. can be 
inflammatory, penetrating or structuring.  
 
A reduction of species diversity was shown in patients with ulcerative colitis. 
This effect was associated with instability of dominant taxa, whereas in healthy 
individuals intraindividual stability and similarity reached approximately 80% (69). In 
the colon of ulcerative colitis patients increased load of Desulfovibrio, bacteria 
generating sulphides was detected (70). Moreover, Fusobacterium varium and 
Fusobacterium nucleateum strains invading epithelium were identified in inflamed 
colon biopsies (71-73). In contrary, anti-inflammatory species such as Fusobacterium 
prausnitzii was reduced during both active disease (74) and remission. 
 
Similar to ulcerative colitis, it was noted that in Crohn’s disease there is 
an instability of dominant species (75). Specific species changes are more difficult to 
describe, because they depend on the affected part of the gut. In ileal Crohn’s disease 
Faecalibacterium and Roseburia were not present, while Enterobacteriaceae and 
Ruminococcus gnavus levels were increased (76). Interestingly, potentially pathogenic 
adherent-invasive E. coli (AIEC) has been isolated form ileal Crohn’s patients (77, 78). 
These bacteria adhere to intestinal epithelial cells, invade them and replicate within 
macrophages but they do not adhere to enterocytes from healthy individuals (79). Thus, 
an imbalance between protective and damaging microbes may play a role in influencing 
mucosal and systemic immunoregulatory responses. 
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5.5 Microbiota recognition by dendritic cells 
DCs are able to recognize a wide variety of microbial structures called pathogen 
associated molecular patterns (PAMPs), which are characteristic for different groups of 
microorganisms. They are recognized by PRRs on the surface of DCs, in endosomes or 
in the cytoplasm. The most well described and phylogenetically conserved group is 
called TLRs. They recognize components of bacteria, viruses and in some 
circumstances also self material. The second group of PRRs are NOD-like receptors 
(NLRs), which are represented by nucleotide-binding oligomerization domain 
1 (NOD1) and nucleotide-binding oligomerization domain 2 (NOD2). The third group 
are RIG-I-like receptors (RLRs). The fourth group of PRRs are C-type lectin receptors 
(CLRs), which bind carbohydrate structures present on microbiota and host cells. 
Additional PRR families exist, but will not be discussed further.  
 
DCs are responsible for shaping T cell responses. For this three signals are 
needed. First is MHC-peptide complex recognition. Second, costimulatory molecules 
expression and third, secreted cytokines such as IL-10, IL-12, transforming growth 
factor beta (TGF-β) and other membrane-bound or soluble molecules such as retinoic 
acid. All of these factors influence the T cell polarization program, which can result in 
Th1, Th2, Th9, Th17, Th22 or Treg responses. The selection of cytokines and other 
molecules involved in these processes depends on the manner by which DCs are 
activated. The final outcome can be the effect of many different PRRs activation on the 
same cell. There is still not too much known about PRRs cross-talk. For instance, 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) signaling modulates TLR signaling through Raf-1 dependent acetylation of p65 
via an unknown mechanism (80). DC immunoreceptor (DCIR) after internalization is 
present in the same compartment as TLR8 and TLR9. In myeloid dendritic cells 
(mDCs) DCIR signaling influences TLR8-mediated TNF and IL-12 secretion, while in 
plasmacytoid dendritic cells (pDCs) DCIR decreases TLR9-induced TNF and IFN-α 
production (81, 82). 
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5.5.1. Toll-like receptors 
 
There are two classes of DCs in human peripheral blood. Plasmacytoid DCs 
express TLR7 and TLR9, while myeloid DCs express TLR1, TLR2, TLR3, TLR4, 
TLR5, TLR6 and TLR8. TLRs are type I membrane glycoproteins conserved from 
Caenorhadbitis elegans to humans (83). Toll was first identified in Drosophila as 
a protein crucial for antifungal responses (84). TLRs consist of ectodomains containing 
leucine-rich repeats, which recognize PAMPs; transmembrane domains and intracellular 
Toll-interleukin 1 (IL-1) receptor (TIR) domains involved in downstream signaling. 
TLRs recognize diverse PAMPs, such as proteins, lipids, lipoproteins, nucleic acid from 
microbes (85). TLR signaling leads to MHC and costimulatory molecule upregulation 
and cytokine secretion, providing DCs with the ability to prime naïve T cells. TLRs play 
an essential role in appropriate immunity against infection, however their inappropriate 
activation leads to acute and/or chronic inflammation. Myeloid differentiation primary 
response protein 88 (MyD88) deficient mice are more susceptible to DSS-induced 
colitis, what suggests that commensals can be recognized by TLRs in steady-state 
condition and contribute to intestinal homeostasis (86). Consistent with this finding 
antibiotic treatment, which depletes the microbiota, also increased susceptibility to DSS, 
while oral feeding with LPS and lipoteichoic acid corrected this tendency (86). 
Interestingly, nonobese diabetic (NOD) mice deficient in innate MyD88 signaling are 
protected against type 1 diabetes and Bacteroidetes species dominate their gut (87). 
However, this protection is lost, when mice are housed under germ-free conditions. 
Moreover, some mutations, single nucleotide polymorphism (SNP) in TLR coding 
genes can cause inappropriate innate immune response and increase susceptibility to 
many diseases. One of the best known examples are mutations in NOD2, which are 
recognized risk factors for the development of Crohn’s disease.  
 
TLRs can be divided into two groups depending on the cellular localization. The 
first group is expressed on the cell surface and consists of: TLR1, TLR2, TLR4, TLR5 
and TLR6 in humans and recognizes mainly secreted or membrane-bound microbial 
components. The second group resides in the intracellular vesicles, such as 
endoplasmatic reticulum (ER), endosomes, lysosomes or endolysosomes. This group 
includes TLR3, TLR7, TLR8, TLR9 and plays role in microbial nucleic acid sensing. 
This special and functional separation allows the cell to respond to different PAMPs 
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from the same microbe. Many pathogens evolved methods to avoid recognition by the 
innate immune system, for instance intracellular pathogens escape from lysosomes and 
survive in cytoplasm.  
 
Classically, TLRs are present on antigen presenting cells (APC), such as DCs, 
macrophages and B cells. In B cell-specific MyD88-/- mice, after DSS treatment, 
bacteria are found in systemic locations, such as lung. This effect is not present in 
epithelial cell-specific or DC specific-MyD88-/- mice (88). MyD88 signaling in B cells 
in steady-state helps to control amounts of IgE in serum and circulating basophiles. 
When B cells are deficient in MyD88 IgE level is increased in serum and more IgE 
binds to basophiles (89.) Interestingly, there is growing evidence showing TLRs 
expression on the surface of T cell subsets (90). This opens new perspectives for direct 
influence of microbes and/or their metabolites on T lymphocytes. RAG-deficient mice 
have decreased inflammation after transfer of MyD88-deficient T cells (91). Moreover, 
CD4+ lymphocytes treated with TLR4 agonist  have elevated suppressive function and 
protect against colitis (92). 
 
5.5.1.1 Surface TLRs 
 
The best described cell surface TLR is TLR4, which responds to LPS from 
Gram-negative bacteria. In order to bind LPS, TLR4 forms a complex with MD2, 
however LPS binding requires additional steps. LPS-binding protein (LBP) soluble in 
the plasma binds LPS. Next LBS is bound by CD14 and finally LPS is delivered to 
TLR4-MD2 complex (93). In addition TLR4 recognizes other PAMPs, such as 
Streptococcus pneumonia derived pneumolysin, mouse mammary tumor virus envelope 
protein and respiratory syncytial virus fusion protein (85). 
 
TLR2 is deeply investigated as it recognizes a very wide range of PAMPs. This 
includes: lipoproteins, peptidoglycan, lipoteichoic acid, lipoarabinomannan from 
mycobacteria, zymosan, tGPI-mucin from Trypanosoma cruzi, hemagluttinin protein 
from measles virus and polysasccharide A (PSA) (94). Moreover, TLR2 can form 
heterodimers with TLR1 and TLR6, which increases the number of recognized PAMPs. 
TLR1 and TLR6 possess different lipid-binding pockets. Therefore TLR1/2 recognizes 
triacetylated lipoproteins, while TLR2/6 binds diacetylated lipoproteins from Gram-
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negative bacteria and mycoplasma. TLR2 is widely described as a PRR mediating host 
protective immune responses. In general, TLR2-/- DCs are not capable to promote 
Foxp3 Treg cells development and IL-10 production in vitro. Bacteroides fragilis 
produces PSA, which influences maturation of the immune system by promoting 
development  of CD4+ T lymphocytes (95). Foxp3+ Treg cells are activated and 
produce IL-10. In this way Bacteroides fragilis induces protective, immunoregulatory 
responses in murine model of inflammatory bowel disease and multiple sclerosis (94, 
96, 97). All these effects are specifically mediated by PSA acting on TLR2, because 
PSA does not protect TLR2-/- mice against colitis (98). PSA is delivered to DCs in 
vesicles, which bud from Bacteroides fragilis outer membrane surface (99). 
Interestingly, PSA enhances the anti-inflammatory activity of Treg cells directly 
through TLR2 expressed on the surface of CD4+ T lymphocytes (98). Moreover, 
another commensal microbe Bifidobacterium breve is recognized by TLR2 on intestinal 
CD103+DCs and promotes Tr1 IL-10 producing cells development, however the exact 
microbial ligand remains unknown (100). TLR2 seems to play important role also in 
restoring skin homeostasis after injury. Recognition of staphylococcal lipoteichoic acid 
(LTA) (derived from commensal bacteria) by TLR2 on keratinocytes was shown to 
attenuate inflammation caused by injury and TLR3 activation. The best described TLR2 
ligands, such as Pam3CSK or LTA from different bacteria, were not able to induce the 
same effect (101). LTA from Lactobacillus plantarum L-137 was shown to increase 
pro-inflammatory IL-12 production and an opposite effect was seen with another strain 
(102). These differences could be related to LTA D-alanine modifications (101, 102). 
 
TLR5 recognizes flagellin and is highly expressed on CD11b+CD103+ pro-
inflammatory DCs in the gut. TLR5-/- mice are non-specifically resistant to Salmonella-
induced typhoid-like disease, whereas in gastroenteritis gut pathology is exacerbated 
(103). Interestingly, TLR5-/- mice develop features of metabolic syndrome and transfer 
of their microbiota to wild-type animals causes similar effects. (104) 
 
5.5.1.2 Intracellular TLRs 
 
TLR3 is an intracellular TLR and is activated by dsRNA, including viral dsRNA 
produced during replication, genomic RNA of reoviruses and certain small interfering 
RNA (siRNA) (85). This PRR triggers an antiviral response, mainly type I interferon 
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secretion. Moreover, TLR3-/- mice are highly susceptible to lethal murine 
cytomegalovirus infection (105). In humans, TLR3 deficiency increases susceptibility to 
herpes simplex virus type 1 (HSV-1) (106). 
 
TLR7 and TLR8 recognize ssRNA. Moreover, TLR7 binds synthetic 
poly(U)RNA and certain siRNA (107). TLR7 can recognize viral RNA and induce type 
I interferon production. This PRR is expressed by pDCs and requires autophagy for the 
most efficient PAMP delivery. When autophagy in pDCs is blocked, vesicular 
stomatitis virus is not sensed correctly (108). 
 
TLR9 recognizes unmethylated 2’-deoxyribo (cytidine-phosphate-guanosine) 
CpG DNA present in bacteria and viruses, such as murine cytomegalovirus, HSV-1 and 
HSV-2 (109). This TLR plays an important role in pDC and B cell activation. CpG 
stimulated B cells increase IL-10 production, while pDCs secrete type I interferon and 
initiate strong antiviral response. Other receptors like CD303 can downregulate this 
proinflammatory response and increase TLR-9 induced IL-10 secretion. 
 
5.5.1.3 TLR signaling 
 
In TLR signaling TIR-domain-containing adaptor molecules, including MyD88, 
TIRAP, TIR-domain-containing adapter-inducing interferon-β (TRIF) and TRIF-related 
adaptor molecule (TRAM), are involved. They are recruited by TLRs and activate 
diverse signaling cascades. MyD88 can be utilized by all TLRs with only one exception 
– TLR3. In this pathway NF-κB and mitogen-activated protein kinase (MAPK) are 
activated and proinflammatory cytokines are produced (85). TLR3 and TLR4 can 
recruit TRIF, which leads to IFN-regulatory factor (IRF)3 activation and type 
I interferon secretion. TRAM and TIRAP are adaptor molecules, which recruit TRIF to 
TLR4 and MyD88 to both TLR2 and TLR4, respectively. Interestingly, TLR4 utilizes 
all 4 adaptors in order to activate both TRIF and MyD88. Moreover, both cascades need 
to be activated for proinflammatory cytokine production in response to TLR4 ligand 
binding. In general TLR signaling can be divided into MyD88- and TRIF-dependent 
pathways (Figure 3). 
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MyD88 recruits IL-1 receptor-associated kinases (IRAKs): IRAK4, IRAK1, 
IRAK2 and IRAKM. TNF receptor-associated factor 6 (TRAF6) interacts with activated 
IRAK and catalyzes polyubiquitination on Lys63 on both TRAF6 and IRAK. This 
promotes binding of TAB2 and TAB3, which create regulatory complex with the TGF-
β-activated kinase 1 (TAK1). Polyubiquitinin chains bind also NEMO, which 
constitutes a regulatory component of IκB kinase (IKK) complex required for NF-κB 
activation. Subsequently TAK1 phosphorylates IKKβ and this results in NF-κB 
activation. This effect is mediated by phosphorylation and degradation of IkB proteins 
(110). TAK1 activates also MAPKs, ERK1/2, p38 and c-Jun N-terminal kinase (JNK). 
TRIF also recruits TRAF6 and activates TAK1 leading to NF-κB activation in similar 
way as in the MyD88-dependent pathway. TRIF binds the adaptor molecule receptor-
interacting protein 1 (RIP1), which is polyubiquinated by Pellino-1 after TLR3 ligand 
binding. Further, TNF receptor type 1-associated DEATH domain protein (TRADD) 
interacts with RIP1 and these 2 steps are critical for NF-κB activation in response to 
TLR3 (111, 112). 
 
 
Figure 3. The cell surface TLR signaling. (Reproduced from Kawai T, Nat Immunol 2010) 
Surface TLRs activate two signaling pathways after ligand binding. MyD88-dependent pathway leads to 
NF-κB activation and pro-inflammatory cytokines secretion, while TRIF-dependent pathway results in 
NF-κB activation and pro-inflammatory cytokines production, including type I interferon induction as a 
result of IRF3 activation. (83) 
 
The TRIF-dependent pathway activates IRF3 and IFN-β production in addition 
to NF-κB activation (Figure 3, Figure 4) (113). TRIF recruits noncanonical IKKs TBK1 
and IKKi necessary for IRF3 activation. In this complex IRF3 is phosphorylated, 
Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology,  Kawai T, et al. The role of pattern-
recognition receptors in innate immunity: update on Toll-like receptors. 11:373-84, copyright 2010. 
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dissociate and subsequently trans locates to the nucleus. This complex is functional only 
in presence of TRAF3, which is important also for TLR7 and TLR9 signaling (114). 
Moreover, TRAF3 can be involved in inhibition of the MyD88-dependent signaling 
cascade. 
 
TLR7 and TLR9 signaling require IRF7 and MyD88 activation for type 
I interferon expression (Figure 4). IRF7 binds MyD88, IRAK4, TRAF6, TRAF3, 
IRAK1 and IKKα (113). In this complex IRF7 is phosphorylated, dissociates and 
translocates to nucleus. Moreover, TRAF6 can be involved in ubiquitination of IRF7 
resulting in its activation. 
 
 
 
Figure 4. The intracellular TLR signaling. (Reproduced from Kawai T, Nat Immunol 2010) 
Intracellular TLRs activate two signaling pathways after ligand binding. MyD88-dependent pathway 
leads to NF-κB and IRF7 activation, inducing pro-inflammatory cytokines secretion. TRIF-dependent 
pathway results in NF-κB activation and pro-inflammatory cytokines production, including type I 
interferon induction as a result of IRF3 activation. (83) 
 
Activation of MyD88-dependent pathway influences many genes related to NF-
κB transcription. IkBξ  is inducible coactivator for NF-κB p50 subunit and is involved 
in IL-6 and IL-12p40 induction (115). C/EBPδ maximizes IL-6 production (116), while 
Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology,  Kawai T, et al. The role of pattern-
recognition receptors in innate immunity: update on Toll-like receptors. 11:373-84, copyright 2010. 
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IkB-NS suppresses both IL-6 and TNF expression. This effect is achieved via 
modulation of NF-κB p65 subunit binding to DNA (117).  
 
TLR signaling is negatively regulated by a number of inhibitory molecules, such 
as SOCS1 (suppressor of cytokine signaling 1) or MyD88s (MyD88 short) (118). 
Moreover, Src homology phosphatase-1 (SHP-1) negatively regulates MyD88-
dependent pathway. It suppresses IRAK1 and IRAK2 (119). 
 
5.5.2. NOD-like receptors 
 
The second group of PRRs are NLRs. The NOD subfamily is represented by 
NOD1 and NOD2, encoded by card4 and card15, respectively. They recognize 
muropeptide motif mainly from gram-negative bacterial peptidoglycan (PTGN) and 
muramyl dipeptide (MDP), respectively (120, 121). After ligand binding by NODs NF-
κB is activated and pro-inflammatory cytokines are produced. PTGN can enter blood 
circulation and prime killing of some bacterial pathogens. After bacterial depletion, 
lower levels of circulating PTGN is detected and neutrophils are less efficient in killing 
Streptococcus pneumonia and Staphylococcus aureus (122). NOD2 mutations are 
known to potentiate TLR-driven NF-κB activation in Crohn’s patients. However, NF-
κB activation occurs more efficiently through TLRs and NOD2 more specifically 
induces IL-1β release (123).  In contrary, nuclear oligomerization domain proteins 
subfamily C (NLRC)3 and NLRC5 are less well described and are recently discovered 
NOD subfamily members. NLRC3 is involved in MyD88-dependent NF-κB activation 
inhibition via TRAF6 modification (124). NLRC5 expression is induced by IFN-γ, LPS 
stimulation and viral infections. However, the role of this receptor in vivo is not well 
understood. 
 
The NLRP subfamily consists of NLRP1 to NLRP12.  NLRP1, NLRP2, NLRP3 
and NLRC4 are well known for their ability to create a complex called an 
inflammasome (124). Ligand activated receptor interacts with ASC and pro-caspase-1, 
creating the basic inflammasome unit. The inflammasome unit cleaves pro-caspase-1 to 
caspase-1, which cleaves pro-IL-1β to active IL-1β.  The most investigated is the 
NLRP3 imflammasome. It is activated by numerous PAMPs, danger-associated 
molecular patterns (DAMPs) and other factors, such as silica, alum and uric acid 
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crystals. From various PAMPs β-glucan from Candida and Saccharomyces was shown 
to  activate NLRP3 inflammasome and led to IL-1β production (125, 126). Moreover, 
M2 protein from influenza A virus activates this inflammasome (127). 
 
5.5.3. RIG-I-like receptors 
 
The RLR family of PRRs consists of only three members: retinoic acid inducible 
gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and RIG-I like 
receptor LGP2. They are responsible for detecting viruses (128). The first two are 
cytoplasmatic DEx(D/H) box helicases detecting viral products, such as genomic RNA 
and providing the signal for type I interferon production (128). Moreover, RIG-I can 
recognize RNA harboring 5’-triphosphate ends (129). In contrast, MDA5 activation is 
specific to picornavirus infection  or long dsRNA, such as poly(I:C) (130, 131). 
 
The signaling cascade for RIG-I and MDA5 includes  homotypic caspase 
activation and caspase recruitment domain (CARD) domain interaction with interferon 
promoter-stimulating factor 1 (IPS-1) adaptor protein (132). This results in RIG-I and 
MDA5 recruitment to outer membranes of the mitochondria. The whole signaling 
complex activates interferon regulatory factors (IRFs) and other transcription factors. 
Finally, IFN-α and IFN-β secretion is induced (133). 
 
LGP2 does not have a CARD domain and for long time was thought to be 
negative regulator of RLRs.  However, in LGP2-/- mice responses to viruses recognized 
by RIG-I  and to picornaviruses were impaired (134). Finally, it was suggested that 
LGP2 facilitates virus recognition by other RLRs through its ATPase domain (134). 
Recently, LGP2 was shown to be required for antigen specific CD8+ T cell responses 
during West Nile virus infections (135). 
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5.5.4. C-type lectin receptors 
 
The fourth group of PRRs are CLRs, which bind carbohydrate structures present 
on microbes and host cells. They are divided into two families: family I (mannose 
receptor family) – contains several carbohydrate recognition domains (CRDs) in the 
extracellular domain and family II (asiaglycoprotein receptor family) – contains only 
one CRD (136). Family II is divided into two subfamilies: DC-associated C- type lectin 
1 dectin-1 (CLEC7A)  and DCIR (CLEC4A) (Table 1). They play a role not only in 
antigen capture but also in interactions with other cells. 
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Family I 
Receptor Cells Ligand 
Mannose receptor (CD206) mDCs and macrophages 
High mannose and fucose, 
sulphated sugars 
DEC205 (CD205) mDCs Not determined 
Family II 
DC-SIGN (CD209) mDCs Fucose and mannose 
MGL mDCs and macrophages Terminal GalNAc 
MDL1 Monocytes and macrophages Not determined 
Langerin 
Langerhans cells and dermal DC 
subsets 
High mannaose, fucose and 
terminal GalNAc 
Family II, dectin-1 subfamily 
Dectin-1 
mDCs, macrophages, monocytes 
and B cells 
β-1,3-glucan 
MICL 
mDCs, monocytes, macrophages 
and neutrophils 
Not determined 
CLEC2 platelets podoplanin, rhodocytin 
DNGR1 
BDCA+ DCs, monocytes and B 
cells 
Not determined 
CLEC12B macrophages Not determined 
Family II, DCIR subfamily 
Dectin-2 
mDCs, pDCs, monocytes, 
macrophages, neutrophils and B 
cells 
High mannose 
BDCA2 (CD303) 
pDCs, monocytes and 
macrophages 
HCV glycoprotein E2, asialo-
galactosyl-oligosaccharides with 
terminal β-1,4- and β-1,3-
galactose residues, HIV-1 
envelope glycoprotein gp120 
Mincle 
mDCs, monocytes and 
macrophages 
α-mannose, trehalose dimycolate 
DCIR 
mDCs, pDCs, monocytes, 
macrophages, neutrophils and B 
cells 
glycan structures Lewis(b) and 
Man3 
 
Table1. CLRs classification. Cell specific expression patterns and their ligands are 
described. (80, 137-141) 
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CLR family I is represented by mannose receptor and CD205, which is deeply 
investigated in context of therapeutic vaccines development in the field of autoimmune 
diseases. Targeting of β-cell antigens to CD205 results in deletion of antigen-specific 
autoreactive CD8+ lymphocytes in murine model of type I diabetes (142, 143).  
 
The best described CLR representing family II is DC-SIGN/CD209, which binds 
viruses and bacteria, for instance HIV-1, Ebola and Mycobacterium tuberculosis and 
Helicobacter pylori (144). This receptor signaling cascade was shown to interfere with 
TLR signaling and it is dependent on NF-κB activation. Recent studies on DC-SIGN 
have shown that mannose or fucose binding can lead to different signaling cascades due 
to the dynamic regulation of signalosome  in the DCs and thereby change the cytokine 
secretion pattern in a pro- or anti-inflammatory direction (145). DC-SIGN is also 
involved in secreted immunoglobulin (Ig)A-antigen complex transport in the intestine 
(146). DC-SIGN has close homologue L-SIGN present on specialized liver and lymph 
node endothelial cells and both are not expressed on mouse cells. There are several 
mouse homologs of human DC-SIGN and L-SIGN: mDC-SIGN and mSIGNR1 to 
mSIGNR4. The most studied is mSIGNR1, which has similar binding characteristics to 
human DC-SIGN. However, mSIGNR1 is expressed on marginal zone macrophages, 
peritoneal macrophages and LP DCs (147, 148). 
 
Another CLR family II member, macrophage galactose-type lectin (MGL), 
recognizes rare terminal GalNAc structures, and interestingly MGL activation interferes 
with effector T cell cytokine secretion and proliferation via CD45 engagement. In some 
cases it can lead to T cell death (149). 
 
Dectin-1 is a family II dectin-1 subfamily member and modulate dendritic 
activation via noncanonical and canonical NF-kappaB activation through Raf-1 and Syk 
and induce both pro-inflammatory and anti-inflammatory cytokines (145). Dectin-1 
recognizes beta-(1,3)-glucans and is the primary fungal PRR. Many fungi are 
recognized by dectin-1, including Candida albicans, Aspergillus fumigatus, 
Coccidioides, Penicillum, Saccharomyces and Pneumocystis carinii.  Activation of this 
receptor by curdlan (dectin-1 agonist) or pathogenic fungus leads to Th17 and Th1 
differentiation (150). Dectin-1 is necessary for appropriate lung defense during acute 
Aspergillus fumigatus infection. However, during chronic inflammation caused by 
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constant exposure to this fungus dectin-1 contributes to inflammation via the induction 
of IL-22 (151). Dectin-1 plays a critical role in the response to Candida albicans 
infection. Activation of this receptor results in IFN-β production in a Syk and IRF5-
dependent manner (152). Recently, dectin-1 was shown to be important for commensal 
fungi recognition. Dectin-1 deficient animals were more susceptible to  chemically 
induced colitis as a result of changes in responses to resident fungi (2). This result is 
consistent with SNPs in dectin-1, which correlated with very severe cases of ulcerative 
colitis. 
 
CD303 represents the last CLR group: II family, DCIR subfamily. This receptor 
is expressed on pDCs and has no murine homologue (153). It inhibits TLR9 induced 
IFN-α production (154) and TNF-realted apoptosis inducing ligand (TRAIL) (155). 
CD303 signaling inhibits antigen processing and further T cell responses. It blocks CpG 
TLR9 stimulation induced CD40 and CD88 expression (156, 157). This subfamily 
includes dendritic cell immunoactivating receptor (DCAR) and DCAR1, which are not 
found in humans. They can be activating receptors but their role is not fully understood. 
DCAR transcripts were detected in bone marrow-derived dendritic cells (BmDCs), 
lungs, spleen and at low level in the skin and lymph nodes of mice (158). DCAR1 is 
specific to CD8+ DCs in the spleen and thymus and some CD11b+ cells in the spleen 
and bone marrow (159). 
 
5.5.5. Plasmacytoid and myeloid dendritic cells 
 
As mentioned previously, pDCs and mDCs express different sets of PRRs. This 
enables them to recognize diverse PAMPs from the same microbe and coordinate 
adaptive response in a proper way. These two subsets of DCs can be detected by use of 
specific markers. Moreover, pDCs have a morphology similar to plasma cells and only 
after activation they change shape and dendrites are visible. 
 
Human blood contains two mDC subsets: CD141+ and CD1c+. Classicaly 
CD1c+ mDCs are CD11chi, CD11b+, while CD141+ mDCs are CD11clow and CD11b-. 
Human pDCs express on their surface CD123, CD303 and CD304 (Figure 5). 
Moreover, CD141+ mDCs are involved in cross-presentation and interact with CD8+ 
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T lymphocytes. In contrast CD1c+ mDCs present antigens on MHC II to CD4+ T cells. 
pDCs are known to be very efficient source of type I interferons.  
 
 
 
 
 
 
 
Figure 5. Human blood dendritic cell populations and their markers. (Reproduced from 
Collin M, Nat Rev Immunol 2011) Myeloid dendritic cells are divided into two subsets: CD141+ and 
CD1c+. Plasmacytoid dendritic cells express CD123, CD303 and CD304. (160) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmacytoid dendritic cell 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology,  Collin M, et al. Human 
dendritic cell deficiency: the missing ID? 11:575-83, copyright 2011. 
Myeloid dendritic cells 
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5.6 Dendritic cell metabolic immunoregulatory factors  
 
Activated DCs secrete anti- or pro-inflammatory cytokines and upregulate 
CD80, CD86 and MHC II expression. However, there are many immunoregulatory 
factors, which can be produced by DCs in response to PAMPs and other endogenous or 
exogenous stimuli, such as adenosine and histamine. For instance cAMP can be 
elevated after certain GPCRs activation and inhibit antigen presentation and IL-10 
secretion. The best described DC metabolic immunomodulatory factors are 
indoleamine-2,3-dioxyganese (IDO) and retinoic acid, which are discussed in detail in 
next sections.  
 
5.6.1. IDO 
 
 IDO is an enzyme involved in tryptophan catabolism. It is the first enzyme in 
kynurenine pathway and it transforms L-tryptophan into N-formylkynurenine (161). 
IDO is encoded by two genes Ido1 and Ido2, both expressed in mice and humans (162, 
163). In the promoter regions response elements for interferon type I (IFN-α, IFN-β) 
and interferon type II (IFN-γ) are present (164). Moreover, IDO has nonenzymatic 
properties and acts as a signaling protein in long-term TGF-β driven tolerance (165). 
 
IDO activity and physiological importance was described by many groups. This 
enzyme plays a protective role in fetal allografts during murine pregnancy, which was 
confirmed by use of IDO inhibitor 1MT (166). Moreover, blocking IDO activity led to 
exacerbation of autoimmune, allergic and infectious diseases in murine models (167, 
168). In fact, glycosylated allergens can downregulate the level of IDO via the mannose 
receptor, suggesting that CLRs can play an important role in Treg differentiation (169). 
This makes IDO an attractive target for immunotherapy (168).  Recently it was shown 
that CpG-induced IDO activity in pDCs was necessary for Treg suppressor activity and 
blocked their switch to Th17-like cells in the presence of pro-inflammatory mediators 
(170). Moreover, IDO expressed by pDCs blocked the response to melanoma antigens 
in lymph node (LN) (171). Tumor clearance was improved by IDO inhibition, which led 
to IL-6 upregulation and T regulatory cells conversion into Th17 cells (172). Type 
I autoimmune diabetes in NOD female mice was exacerbated after pDC depletion and 
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after IDO inhibition (173). Furthermore, pre-diabetic NOD female mice have a defect in 
IDO expression, which may predispose them to disease development (174).  
It is worth mentioning that IDO can bridge multiple psychological responses, 
such as stress and immune suppression. LPS or chronic inflammation induced IDO 
causes neurologic depression symptoms and anxiety-like behavior (175, 176). In 
contrast, acute stress induces low-grade inflammation, which turns on transient 
tryptophan catabolism dependent on IDO, especially Ido1 gene expression (177). 
Stressful episodes, prolonged lack of tryptophan and kynurenines formation are 
immunosuppressive. Furthermore, when tryptophan is utilized by IDO, serotonin 
production is affected, which can influence subsequent mood alterations and depression 
development  (178). 
 
5.6.2. Retinoic acid 
 
Retinoic acid is present in two different isomeric forms in mice and humans: 
All-trans-retinoic acid is the most abundant form, whereas 9-cis-retinoic acid is present 
at significantly lower concentration. Retinoic acid takes part in many diverse biological 
processes such as cellular differentiation, apoptosis, embryonic development,  
spermatogenesis, and vision (179, 180). 
 
5.6.2.1 Retinoic acid metabolism  
 
Vitamin A (retinol) is obtained from the diet in three forms: all-trans-retinol, 
retinyl esters or β-carotene and transported in the blood as a complex with retinol-
binding protein (RBP) and transthyretin (TTR) (181, 182). Small intestine epithelial 
cells convert vitamin A to retinyl esters, which are transported in chylomicrons via the 
lymph into the bloodstream. In the liver retinyl esters are taken up and stored in the 
stellate cells (181, 182). Retinoic acid is produced within the cell from vitamin A in two 
tightly regulated steps (Figure 6) (183, 184). Retinol and β-carotene are oxidized to 
retinaldehyde (retinal) and further retinal is converted  to retinoic acid. In first steps 
many ubiquitously expressed aldehyde dehydrogenases (ADHs) and short chain 
dehydrogenase reductases (SDRs) are involved. In contrast, retinaldehyde 
dehydrogenases family (RALDH), which irreversibly oxidizes retinal to retinoic acid, 
expression is limited to certain cell types, such as intestinal epithelial cells (185, 186), 
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nerve fibers (187), MLN stromal cells and DCs in PP, MLN, LP (185, 188, 189). 
Splenic and peripheral lymph node DCs express these enzymes at a very low level 
(189). 3 enzymes belonging to RALDH family were well described: RALDH1, 
RALDH2 and RALDH3. RALDH4 is present in mice but its physiological role is 
unknown (190).  RALDH2 and RALDH3 knockouts are lethal (191-193). Only 
RALDH1 knockout is not so critical for survival (194). This enzyme is mainly produced 
by epithelial cells and has been recently associated with possible protection from asthma 
development. RALDH2 is present in MLN and LP CD103+ DC subsets (195), while 
RALDH3 can be detected in PP DCs. In addition to retinoic acid production these 
enzymes directly regulate lipid metabolism. Retinoic acid is released from cells and acts 
in paracrine or autocrine fashion. Moreover, retinoic acid is catabolized in the 
cytoplasm by the CYP26 class of P450 enzymes and its metabolites, such as 4-hydroxy 
retinoic acid and 4-oxo retinoic acid, are eliminated with bile and urine. Retinoic acid 
induces its own degradation by CYP26A1 upregulation (196). 
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Figure 6. Vitamin A (retinol) metabolism in the small intestine. (Reproduced from Mora JM, 
Nat Rev Immunol 2008) Retinol is transported in the blood as a complex with retinol-binding protein 
(RBP) and transthyretin (TTR). It can be stored in the liver as a retinyl ester. In the small intestine retinol 
is converted into retinal by aldehyde dehydrogenases (ADHs) or short chain dehydrogenase reductases 
(SDRs). Next step is irreversible and results in retinoic acid production by retinaldehyde dehydrogenases 
enzymes (RALDH). Retinoic acid interacts with retinoic acid receptor (RAR) and the retinoid X receptor 
(RXR) and subsequently this complex binds to specific retinoic acid response element (RARE) in the 
promoter regions of retinoic acid-dependent genes. Retinoic acid is catabolized in the liver and other 
tissues by the CYP26 and its metabolites are eliminated with bile and urine. (197) 
 
5.6.2.2 Retinoic acid receptors 
 
Retinoic acid acts on different cells by binding to retinoid nuclear receptors, 
such as retinoic acid receptor (RAR) and the retinoid X receptor (RXR) (198). Each 
class of retinoid receptor has three main isoforms, namely α, β, and γ, encoded by 
separate genes. Furthermore, each gene has multiple splice variants (198). These 
receptors form heterodimers (RAR/RXR) or homodimers (RXR/RXR). They are known 
to regulate more than 500 genes (199). RARs are ubiquitously expressed and 
upregulated by retinoic acid (181, 182). RXRs form homodimers, which are specific 
receptors for 9-cis-retinoic acid. This form of retinoic acid can also signal through 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology,  Mora JM, et al. Vitamin effects 
on the immune system: vitamins A and D take centre stage. 8:685-98, copyright 2008. 
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RAR/RXR heterodimers. In contrast, all-trans-retinoic acid binds only to RARs (198). 
RXRs can interact with other nuclear receptors, such as thyroid hormone receptor, 
peroxisome proliferator activated receptor (PPAR) and liver X receptor (200). 
RAR/RXR complexes bind to specific retinoic acid response element (RARE) in the 
promoter regions of retinoic acid-dependent genes (Figure 6). They function as 
transcriptional enhancers or repressors (198, 201). Moreover, retinoic acid can have 
a direct influence on the activation of many transcription factors through the 
phosphorylation of the cAMP response element-binding protein (CREB), the mitogen 
activated kinase ERK1/2, JNK and p38 in neuronal cells (202-204). Retinoic acid 
inhibits the induction of c-Jun and c-fos (205). Interestingly, retinoic acid interacts and 
signals through the PPARβ (also known as PPARδ) nuclear receptor (197, 206). The 
ratio of cellular retinoic acid-binding proteins (CRABPs) to fatty acid-binding protein 
5 (FABP5) determines if signaling occurs through RAR or through PPARβ (206). 
A high CRABP:FABP5 ratio promotes RAR signaling, which results in growth 
inhibition and apoptosis in some cell lines. In contrast, a low ratio favors FABP5-
mediated delivery of retinoic acid to PPARβ and survival in the same cells (206).   
 
5.6.2.3 Retinoic acid production by intestinal CD103+ DCs 
 
DCs in the intestinal mucosa play an important role in regulating the balance 
between tolerance and immunity. They recognize antigen/microbiota, migrate to MLN 
and induce appropriate responses by priming naïve T cells. DCs are present in the 
GALT and LP of the small intestine, while in the large intestine they are mainly placed 
in lymphoid aggregates. CD103+ DCs are a major DC subset in the small intestinal LP. 
In steady state, they continuously migrate to MLN, where they promote tolerance. 
Murine small intestine LP and MLN CD103+ DCs are capable of converting retinol into 
retinoic acid. They express a higher level of Aldh1a2 (gene encoding RALDH2) and 
possess higher RALDH activity than DCs from other tissues, including CD103+ DCs 
from the colon (189, 207- 210). CD103+ DCs from colon express similar levels of RAR 
α, β and γ as CD103+ DCs from small intestine (211). However, lower retinoic acid 
production in the colon can be related  to retinol (substrate) concentrations, which are 
significantly higher in the small intestine and MLNs than in the colon, spleen, serum 
and peripheral lymph nodes (PLNs) (210, 211). 
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MLN CD103+ DCs ability to promote retinoic acid metabolism is closely related 
to their tolerogenic properties (Figure 7). They induce gut homing receptors, such as CC 
chemokine receptor 9 (CCR9) and α4β7 integrin expression on T and B cells (185, 211-
213), enhance TGF-β-dependent Foxp3+ T regulatory cells priming, while suppressing 
Th17 differentiation (189, 213, 214). Moreover, it has been shown that they promote the 
generation of IgA secreting cells (215). It is worth noting that RALDH+ DCs are 
present in other tissues e.g. skin (207). Cutaneous RALDH+ DCs are CD103- and do 
not induce gut homing receptor expression. 
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Figure 7. Role of retinoic acid in the small intestine. (Reproduced from Coombes JL, Nat Rev 
Immunol 2008) In the murine small intestine many cells are capable of converting retinol into retinoic 
acid (RA). Epithelial cells and PP dendritic cells (DCs) express Aldh1A1, while MLN CD103+ DCs 
express Aldh1A2.  Intestinal CD103+ DCs ability to promote retinoic acid metabolism is tightly related to 
their tolerogenic properties. They induce gut homing receptors, such as CCR9 and α4β7 integrin 
expression on T and B cells, enhance TGF-β-dependent Foxp3+ T regulatory cells priming, while 
suppressing Th17 and Th1 differentiation. Moreover, they promote the generation of IgA secreting cells. 
(216) 
 
As vitamin A is a substrate for retinoic acid production, dietary vitamin 
A impact on intestinal CD103+ DCs was assessed in vitamin A deficient mice (VAD). 
These mice are kept on vitamin A deficient diet from embryonic day 11 until adulthood. 
This deficiency dramatically reduced Aldh1a2 expression and RALDH activity in 
CD11c+ MLN DCs (217), which were mainly CD103+ (195, 211). At the same time, 
CD103+ DCs frequency was not changed in the whole gut (195). Both vitamin A and 
retinoic acid oral supplementation restored this activity (195, 210,  218).  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology,  Coombes JL, et al. Dendritic 
cells in intestinal immune regulation. 8:435-46, copyright 2008. 
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As mentioned earlier, cells other than DCs are involved in retinoic acid 
metabolism in the gut. The small intestine epithelial cells can convert retinol (219) and 
have been correlated with tolerogenic DCs imprinting (in vitro experiments) (220, 221). 
Moreover, murine macrophages express Aldh1a2 gene and possess RALDH activity but 
at lower level than CD103+ DCs  (207, 222).  
 
5.6.2.4 Regulation of retinoic acid metabolism  
 
Retinoic acid metabolism has been shown to be regulated through TLR 
signaling. Many PAMPs including TLR2 homodimer ligands, such as zymosan and 
Pam-2-cys, TLR2/TLR1 heterodimer ligand Pam3CSK4 and TLR2/TLR6 heterodimer 
ligand follistatin induced RALDH activity and Aldh1a2 expression (207, 210, 223, 
224). The signaling cascade leading to vitamin A metabolism enhancement is not clear, 
because various TLR2 homodimer and heterodimer ligands activated different 
pathways. Pam3CSK4 mediated JNK/MAPK signaling and pan-JNK inhibitor 
decreased vitamin A metabolism (223), whereas zymosan acted via ERK (Figure 8) 
(224). Nevertheless, TLR signaling alone seems to be not sufficient for Aldh1a2 
induction in the small intestine DCs and many studies have showed contradictory 
results. MLN CD103+ DCs in one study presented normal RALDH activity in MyD88-/- 
and TRIF-/- mice (195), while others have found small but a significant decrease in 
RALDH activity in MyD88-/-  mice (223) and  MyD88-/-TRIF-/- mice (207), which could 
be related to lower RARβ expression and impaired autocrine retinoic acid effect on 
DCs. Moreover, TLR-dependent regulation seems to work only through TLR2 as TLR4 
and TLR6 did not affect vitamin A metabolism in MLN CD103+ DCs. Only DCs from 
TLR2-/- mice had reduced metabolism and ability to induce gut homing receptors on 
T cells (223). Albeit the role for TLR2 remains controversial, because of low level 
expression on the surface of the small intestine CD103+ DCs (225, 226). 
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Figure 8. Molecular pathways involved  in vitamin A metabolism induction.  (Reproduced 
from Pulendran B, Nat Immunol 2010) Ligand binding to TLR2/TLR6  leads to ERK activation, which 
results in retinaldehyde dehydrogenase 2 (RALDH2) induction and retinoic acid (RA) production. RA 
exerts autocrine effect on DC by binding to retinoic acid receptor (RAR) and the retinoid X receptor 
(RXR). This leads to RALDH2 and suppressor of cytokine signaling 3 (SOCS3) upregulation. IL-10 also 
enhances expression of both RALDH2 and SOCS3. Moreover, activation of  β-catenin pathway by TLRs, 
Wnt ligands or E-cadherin promotes anti-inflammatory factors, such as RA, IL-10 and TGF-β production. 
Further, IL-10, RA and TGF-β contribute to Treg and Tr1 cells induction. (227) 
 
Other potential regulators of vitamin A metabolism in CD103+ DCs were tested 
in in vitro assays and murine models. Cytokines, such as granulocyte macrophage 
colony-stimulating factor (GM-CSF), IL-4 and IL-13 induced RALDH activity in 
BmDCs, splenic DCs and human MDDCs (217, 228). This finding was confirmed in 
vivo in MLN CD11c+ DCs from mice deficient in the GM-CSF/IL-3/IL-5 subunit 
receptor (217). Albeit these mice had reduced numbers of intestinal CD103+ DCs (229) 
and another study has shown no alteration in retinoic acid metabolism in MLN DCs 
(223). The role of IL-4 has not been clearly described. One study suggested lower 
Aldh1a2 expression in IL4ra-/- mice (230), while another one suggested no changes in 
RALDH activity (217). Furthermore, PPARγ agonists, such as rosiglitazone, induce 
vitamin A metabolism in human MDDCs (206) and murine splenic DCs (231) through 
upregulation of retinol dehydrogenase 10 (RDH10), RALDH2 and CRABP2 expression 
(232).  
Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology,  Pulendran B, et al. Programming 
dendritic cells to induce T(H)2 and tolerogenic responses. 11:647-55, copyright 2010. 
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Retinoic acid can directly induce RALDH activity and RALDH2 expression in 
BmDCs and splenic DCs in an autocrine manner. These cells can further promote gut 
homing receptor expression on T cells and Treg differentiation (195, 211). The 
signaling cascade, which potentiates retinoic acid metabolism is still not well 
understood. Retinoic acid self-upregulation requires protein synthesis and is blocked by 
cycloheximide (translational inhibitor) (210). ERK seems to be involved, because its 
inhibitor UO126 reduces RALDH activity in MLN DCs (210). Many other factors were 
tested in order to elucidate signaling cascades leading to retinoic acid metabolism or 
inhibition. The role of prostaglandin E2 (PGE2) on RALDH2 expression in DCs was 
investigated. PGE2 inhibited RALDH2 expression in BmDCs stimulated with 
cytokines. Furthermore, lower levels of PGE2 resulted in changes in RALDH activity in 
splenic DCs (228). The proposed suppression mechanism includes inducible cAMP 
early repressor (ICER) expression, which was detected in MLN and peripheral lymph 
node (PLN) DCs displaying RALDH activity. However, PGE2 levels are similar in non-
gut tissues and thus PGE2 does not seem to be critical regulator of vitamin 
A metabolism. Recently, β-catenin deficiency in CD11c+ cells was shown to induce an 
inflammatory pattern in LP DCs and macrophages (233). Small intestine CD103+ DCs 
had reduced RALDH2 expression suggesting interaction between WNT-β-catenin 
signaling and pathways regulating retinoic acid metabolism (Figure 8). However, 
cellular regulation of vitamin A metabolism remains unknown. 
 
5.6.2.5 Retinoic acid direct effect on DCs 
 
Retinoic acid has direct effect on DCs. It regulates antigen presentation, 
increases matrix metalloproteinases, which leads to more efficient migration to lymph 
nodes and was described to potentially boost specific T cell responses against tumors 
(234). In inflammatory condition (for instance high levels of TNF-α) retinoic acid 
signaling through RXRs enhances DC maturation and antigen presentation capacity 
(235). Moreover, if DCs are pre-treated with retinoic acid, they are able to store this 
metabolite (236) and release it in close proximity to other cells, such as T cells. 
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5.6.2.6 Retinoic acid effects on T and B lymphocytes 
 
Retinoic acid affects many T cell properties, such as cytotoxicity (237) and 
proliferation (238). Furthermore, studies in VAD mice have revealed defects in T helper 
cells activity (239), which can be explained by impairment in competing with 1,25-
dihydroxyvitamin D3 for RXR. More specific regulation by retinoic acid seems to 
influence the balance between Th1, Th2 subsets and especially Treg cells and Th17 
subset. 
 
Vitamin A deficiency in mice has been correlated with decreased Th2 responses 
(240), while vitamin A supplementation blocked Th1 effector cytokines (241, 242). 
Interestingly, retinoic acid can promote Th2 differentiation by inducing IL-4 and 
GATA, MAF and signal transducer and activator of transcription 6 (STAT6) expression 
and decreasing T-bet (241, 243, 244). In the mouse model of asthma vitamin 
A supplementation increased disease severity (245).   
 
Regulation of Th17 and Treg cell balance by retinoic acid has been intensively 
investigated. TGF-β supports Treg generation in the periphery (246), albeit retinoic acid 
can enhance it significantly (Figure 9) (215, 247) by acting on RARα (248). 
Furthermore, retinoic acid inhibits Th1 and Th17 development (215, 249, 250). 
Especially effective in this process are DCs from GALT and the small intestine (189, 
214 Moreover, retinoic acid upregulates gut homing receptors CCR9 and α4β7 
expression on activated T cells (Figure 9) (214, 247).  These cells migrate to the gut in 
response to CCL-25 and mucosal addressin cellular adhesion molecule (MAdCAM). 
The role of retinoic acid was confirmed in several  in vitro assays. 1nM retinoic acid 
induced α4β7 integrin on T cells. In contrast, RALDH inhibition by citral or RAR 
signaling inhibition by LE540 blocked CCR9 and α4β7 expression on T lymphocytes 
(185). Furthermore, LP, PP, MLN CD103+ DCs imprinted naïve T cells and B cells 
(251) with the ability to migrate to the gut (185, 213, 230). It is worth mentioning that 
this migration is specific for small intestinal and not for colonic DCs (252).  
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Figure 9.  Retinoic acid induces gut homing receptor expression on Treg cells. (Reproduced 
from Campbell DJ, Nat Rev Immunol 2011) Retinoic acid produced by intestinal CD103+ dendrtitic cells 
(DCs) induces CCR9 and α4β7 expression on naturally occurring thymus-derived Treg cells and on de 
novo differentiated inducible Treg (iTreg) cells. Moreover, retinoic acid supports TGF-β during iTreg 
induction.  (253) 
 
Vitamin A metabolism in the gut also regulates B cell functions, such as class 
switching to IgA (213) antibody production in response to bacterial antigens. Depending 
on local conditions, retinoic acid can act on other B cell features, for instance inhibit B 
cell proliferation, enhance B cell activation (236, 254) or inhibit B cell apoptosis. All 
these effects are mediated through RARs (255). Retinoic acid influence on class switch 
was analyzed by many groups. The presence of retinoic acid induces IgA secretion by 
LPS activated splenocytes (256) or B cells stimulated with LPS co-cultured with splenic 
DCs (257). However, retinoic acid, without DCs, during purified B cells activation is 
not sufficient for IgA class switch (213, 257). Also required are IL-5 (213, 256) or IL-6 
(213, 258), which are generally involved in IgA production (231, 259). Moreover, 
inducible nitric oxide synthase (iNOS), whose promoter contains RARE (260), and 
nitric oxide also contribute to IgA class switch (261). Albeit, experiments done in VAD 
mice have shown that retinoic acid is not needed for IgA+ antigen specific cells (ASCs) 
generation in other mucosal compartments than gut. Numbers of IgA+ ASCs were 
decreased in the small intestine  (213, 262), while serum levels stayed normal (213). 
 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology,  Campbell DJ, et al. 
Phenotypical and functional specialization of FOXP3+ regulatory T cells. 11:119-30, copyright 2011. 
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5.7 Immunoregulation by microbes  
 
As it was discussed in this introduction, microbiota in the gastrointestinal tract 
impacts many physiological processes. It has been shown to influence digestion, 
nutrient absorption, host metabolism and immune function. In many diseases, microbial 
composition in the gut is changed, however it remains unknown if this alteration causes 
disease or it is a consequence of a prolonged inflammatory condition. Tolerogenic 
microbes help to keep the balance between anti- and pro-inflammatory responses and 
may be beneficial in the treatment of the gut and non-gut inflammatory disorders. The 
complicated multicellular signaling networks activated by commensal microbes are 
involved in this process and require further detailed investigation. This thesis is focused 
on developing a better understanding of a specific commensal bacterium 
Bifidobacterium infantis 35624, which has been previously shown to possess strong 
immunoregulatory properties. 
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6. Aims 
 
B. infantis is commensal bacterium which has been previously shown to protect 
against inflammatory diseases in murine models e.g. colitis and respiratory allergy. The 
protective host immune response in murine models was demonstrated to include the 
induction of T regulatory cells. However, the molecular basis for the Foxp3 regulatory 
T cells induction by specific microbes is poorly understood and was not deeply 
investigated for this microbe. 
 
The aims of this thesis were: (1) to elucidate the molecular mechanisms 
responsible for B. infantis recognition and monocyte derived dendritic cells (MDDCs), 
myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs) activation; (2) To 
analyze the effect of activated dendritic cell subsets on naive T cell priming; (3) to 
determine if B. infantis induces retinoic acid production by mucosal CD103+ DCs; (4) to 
analyze the role of B. infantis- induced retinoic acid metabolism in protection against 
DSS-induced colitis. 
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7. Results 
 
7.1 Bifidobacterium infantis 35624 administration induces Foxp3 T 
regulatory cells in human peripheral blood; potential role for myeloid and 
plasmacytoid dendritic cells 
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7.2 Immunomodulation by Bifidobacterium infantis 35624 in the murine 
lamina propria requires retinoic acid-dependent and independent mechanisms 
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ABSTRACT 
Appropriate dendritic cell processing of the microbiota promotes intestinal 
homeostasis and protects against aberrant inflammatory responses. Mucosal CD103+ 
dendritic cells are able to produce retinoic acid from retinal, however their role in vivo 
and how they are influenced by specific microbial species has been poorly described.  
Bifidobacterium infantis 35624 (B. infantis) feeding to mice resulted in increased 
numbers of CD103+retinaldehyde dehydrogenase (RALDH)+ dendritic cells within the 
lamina propria (LP).  Foxp3+ lymphocytes were also increased in the LP, while TH1 and 
TH17 subsets were decreased.  3,7-dimethyl-2,6-octadienal (citral) treatment of mice 
blocked the increase in CD103+RALDH+ dendritic cells and the decrease in TH1 and 
TH17 lymphocytes, but not the increase in Foxp3+ lymphocytes.  B. infantis reduced the 
severity of DSS-induced colitis, associated with decreased TH1 and TH17 cells within 
the LP. Citral treatment confirmed that these effects were RALDH mediated.  RALDH+ 
dendritic cells decreased within the LP of control inflamed animals, while RALDH+ 
dendritic cells numbers were maintained in the LP of B. infantis-fed mice. Thus, 
CD103+RALDH+ LP dendritic cells are important cellular targets for microbiota-
associated effects on mucosal immunoregulation.  
 
 
 
 
 
 
 
 
 
 
 
85 
 
Results 
 
INTRODUCTION 
The mammalian gastrointestinal microbiota is required for optimal host 
development and ongoing immune homeostasis 1-3.  The microbiota aids in the digestion 
of foods, competes with pathogens, degrades mucin and promotes the differentiation of 
epithelial cells and mucosa-associated lymphoid tissue.  In addition, the composition 
and metabolic activity of the microbiota has profound effects on proinflammatory 
activity and the induction of immune tolerance by influencing a broad range of mucosal 
cell types including epithelial cells, dendritic cells, iNKT cells and T lymphocyte subset 
activity 4-6. 
Gastrointestinal immune homeostasis is dependent on a number of local 
conditioning factors that reduce pathological proinflammatory responses to non-
pathogenic microbes. For example, epithelial-derived cytokines such as TSLP and IL-25 
limit dendritic-cell secretion of IL-12 and IL-23, while promoting IL-10 secretion 7. In 
addition, certain dendritic cell subsets within the mucosa can metabolize vitamin A into 
retinoic acid, such as the CD103+ dendritic cell subset 8, 9.  Retinoic acid is synthesized 
from stored or dietary retinol by the oxidation of retinol to retinal, followed by 
oxidation of retinal to retinoic acid. The final step is catalyzed by aldehyde 
dehydrogenase family 1, subfamily A1 (Aldh1a1) and ALDH1 subfamily A2 
(Aldh1a2), also called RALDH enzymes. 3,7-dimethyl-2,6-octadienal (citral) blocks 
RALDH enzymatic activity. Dendritic cell-derived retinoic acid has dramatic effects on 
dendritic cell activity and lymphocyte subset plasticity. Retinoic acid can have 
seemingly conflicting effects on lymphocyte polarization, such as promoting TH17 cells 
or Treg cells 10. The promotion of TH17 versus Treg phenotypes may be related to the 
local concentration of retinoic acid, the dendritic cell subset secreting retinoic acid, the 
local level of pro-inflammatory mediators and TGF-β, concomitant toll-like receptor 
activation or induction of specific microRNA 11-14. So far, the role of specific microbial 
species in influencing retinoic acid metabolism and CD103+RALDH+ dendritic cells in 
vivo has been poorly understood.  
Bifidobacterium longum subsp. infantis 35624 (B. infantis) was originally 
isolated from resected human healthy gastrointestinal tissue and human clinical studies 
have demonstrated its efficacy in Irritable Bowel Syndrome patients 15, 16.  In addition, 
murine studies have demonstrated that this microbe protects against inflammatory 
disorders across a range of inflammatory conditions including colitis, pathogen 
infection, arthritis and respiratory inflammation 17-20.  Previously, in vitro studies with 
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human dendritic cells suggested that promotion of retinoic acid metabolism by 
B. infantis was a key regulatory feature of this bacterium 21.  In this report, we 
demonstrate that B. infantis feeding to mice results in increased CD103+RALDH+ 
dendritic cells within the mucosa, which are responsible for the suppression of TH1 and 
TH17 lymphocytes and amelioration of dextran sulfate sodium (DSS)-induced colitis.
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METHODS 
Bacteria and animal models 
Wild-type C57BL/6 mice were obtained from Charles River and maintained 
under specific pathogen free conditions. Mice were housed at the AO Research Institute, 
Davos, Switzerland, in individually ventilated cages for the duration of the study, and 
all experimental procedures were carried out in accordance with Swiss law. 
Experimental protocols were approved by the Ethics Committee of the “Amt für 
Lebensmittelsicherheit und Tiergesundheit Graubünden”, application number 2011-15. 
In the first experiment, three groups of mice were utilized (n=8 per group). Group 1 did 
not receive any bacterial supplementation, while groups 2 and 3 were fed B. infantis for 
7 days. Each day lyophilized bacteria were resuspended in sterile water to final 
concentration of 6x108 colony forming units (cfu)/ml. For group 3, 2mg of citral 
(Sigma, St. Louis, USA) was dissolved in 10% DMSO (Sigma) and was injected i.p. 
daily in order to suppress retinoic acid metabolism.  
In the dextran sodium sulfate (DSS) colitis model, five groups of wild-type 
C57BL/6 mice (n=8 per group) were utilized. Group 1 was the negative control group, 
which did not receive B. infantis and were not administered DSS. Group 2 was the 
positive control group as these mice received DSS but not B. infantis. Groups 3 and 
4 were both administered DSS and B. infantis, while group 4 was also injected i.p. with 
citral (as described above). Group 5 received DSS and citral.  Mice were fed B. infantis 
for 7 days before colitis induction. Mice received DSS (TdB Consultancy AB, Uppsala) 
in water (2.5%) for 6 days followed by 2 days without DSS. During this period bacteria 
were administrated daily by gavage (1x109 cfu/mouse). All mice were euthanized on the 
final day of the study using cervical dislocation, which was performed by an 
experienced investigator.  
 
Cell isolation 
Single cell suspensions from mesenteric lymph nodes (MLN) and Peyer’s 
patches (PP) were isolated using C tubes and GentleMACS Dissociator (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to manufacturer instructions. LP cells 
were isolated from the upper part of small intestine (SI). A 5cm long piece of SI was 
washed out with cold calcium and magnesium free PBS (CMF-PBS) containing 1mmol 
dithiothreitol (DTT) and cold CMF-PBS containing 12 mmol EDTA. The SI was cut 
into pieces and vortexed in CMF-PBS containing 0.3 mmol EDTA. After centrifugation 
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(300g/5minutes) tissue was digested for 45minutes at 37C in RPMI containing 25kU/l 
collagenase IV (Sigma), 150mg/l DNase I (Roche, Rotkreuz, Switzerland) and 5% fetal 
calf serum (FCS, Sigma). Cell suspensions were filtered through 70µm cell strainers, 
centrifuged (700g/8minutes) and washed with CMF-PBS containing 5% FCS, 5mg/l 
DNase I, 5mmol/l EDTA. Finally pellets were resuspended in cRPMI (Invitrogen, 
LuBioScience, Luzern, Switzerland).  
 
Flow cytometry and cell imaging 
Anti-mouse CD11b, CD11c, MHCII, CD3, CD19 and CD103 antibodies 
(Biolegend, Lucerna-Chem, Luzerna, Switzerland) were used for characterization of 
dendritic cell phenotypes. RALDH activity was measured with the ALDEFLOUR kit 
(Aldagen, Durham, USA) according to manufacturer instructions. Anti-mouse CD3, 
CD4, CD25, LPAM-1 (integrin α4β7) and CCR9 antibodies (Biolegend) and anti-mouse 
Foxp3, IL-10, IL-4, IL-17A, IFN-γ antibodies (eBioscience San Diego, CA, USA) were 
used to characterize lymphocyte phenotypes. Cells for intracellular cytokine staining 
were pre-stimulated for 4 hours with PMA (50ng/ml, Sigma) and ionomycin (500ng/ml, 
Sigma) in the presence of Brefeldin A (1µg/ml, eBioscience). Flow cytometric analysis 
was performed using a 10 colour Galios flow cytometer (Beckman Coulter, Brea, USA). 
Kaluza (Beckman Coulter) was used for data analysis. 
MLN and LP cells were incubated in vitro for 1 hour with CFSE labeled B. 
infantis. Cells were stained with anti-mouse CD11c and CD103. Bacteria binding was 
visualized using multispectral imaging flow cytometer Image Stream X (Amnis 
Corporation, Seattle, USA) and images were analyzed using IDEAS software (Amnis 
Corporation).  
 
Histology 
Colons were removed, flushed with PBS and wrapped around to generate a swiss 
roll. Swiss rolls were fixed in 4% paraformaldehye for 12 hours and stored in PBS until 
paraffin embedding. Following embedding, 3 µm thick sections were stained with Gill’s 
hematoxylin and eosin (Sigma). Mounting was done with Eukitt ® quick-hardening 
mounting medium (Sigma). Tissue samples were analyzed by a pathologist in a blinded 
manner. The histology score included assessment of crypts dilatation, inflammatory 
cells infiltration in LP, inflammatory cells infiltration in submucosa, necrosis of 
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epithelium and submucosal edema. Each parameter was scored from 0 to 5 resulting in a 
maximum score of 25.  
 
Myeloperoxidase (MPO) activity test 
Pieces of colon were homogenized in 50mM potassium phosphate buffer, pH 
6.0, containing 0.3% hexadecyltrimethyl-ammonium bromide (HTAB, Sigma). Tissue 
was sonicated on ice for 15 seconds followed by 3 freeze-thaw cycles. Samples were 
centrifuged and 20µl of the supernatant was mixed with 200µl freshly prepared 50mM 
potassium phosphate buffer, pH 6.0, containing 0.3% HTAB, O-dianisdine 
dihydrochloride (0.167mg/ml, Sigma) and 0.5% hydrogen peroxide (Sigma). Change in 
absorbance was measured at 450nm over 4 min. by an ELISA plate reader.  
 
Cytokine assay 
1x106 SI-LP cells were cultured in 1ml cRPMI containing amphotericin B 
(6,25µg/ml, Sigma) and gantamycin (12,5µg/ml, Sigma) and supernatants were 
collected after 24 hours. Cytokine secretion was examined by Bio-Plex multiplex 
suspension array (Bio-Rad Laboratories, Hercules, USA). 
  
Statistics 
Unpaired student t-tests were used to analyse data with a normal distribution, 
while the non-parametric Mann-Whitney test was used to analyze the non-parametric 
data. All data analysis was carried out using GraphPad Prism software. A p value of 
<0.05 was used as the cutoff for statistical significance. 
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RESULTS 
B. infantis is sampled by Peyer’s patch and lamina propria dendritic cells 
Dendritic cells within the LP and Peyer’s patches (PP) have been previously 
described to sample bacteria from the gastrointestinal lumen. In order to determine 
whether B. infantis was sampled by dendritic cells from either site, CFSE-labelled 
bacteria were gavaged to mice and single cell suspensions were generated from ileal LP 
and PP after 2 hours.  Within the PP, CD11c+MHCII+ dendritic cells were identified, 
which had become CFSE positive 2 hours after feeding (Figure 1a). CD11c+MHCII+ 
dendritic cells within the LP also became CFSE positive at 2 hours and with higher 
frequency (Figure 1a).   The presence of CFSE-labelled bacteria attached to, or 
internalized by,  PP dendritic cells at 2 hours was confirmed using multispectral flow 
cytometry imaging (Figure 1b). 
 
Figure 1. B. infantis is sampled by dendritic cells within PP and LP. 
(a) Flow cytometric analysis of CD11c+MHCII+ dendritic cells within the PP and LP at 0 or 2 
hours following gavage of CFSE-labelled B. infantis, revealed that a subpopulation of dendritic cells at 
both sites become CFSE+. (b) Visualization by multispectral flow cytometry imaging confirmed the 
presence of CFSE-labelled bacteria on PP dendritic cells at 2 hours. 
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B. infantis induces CD103+ retinoic acid secreting dendritic cells 
We examined CD103 expression and retinoic acid secretion by dendritic cells in 
mesenteric lymph nodes (MLN) and ileal LP following B. infantis feeding for 7 days.  
B. infantis feeding was associated with a significant increase in the percentage of 
dendritic cells that were CD103+ and metabolizing retinoic acid in the LP, while the 
increase in retinoic acid metabolizing CD103+ dendritic cells in the MLN approached 
statistical significance (Figure 2a). Citral treatment, which blocks retinoic acid 
metabolism, reduced the B. infantis-induced increase in CD103+ and retinoic acid 
metabolizing dendritic cells within the LP. In order to determine if the increase in 
retinoic acid metabolism was a direct effect of B. infantis binding to CD103+ dendritic 
cells, in vitro co-incubation with mucosal dendritic cells demonstrated that CD103+ 
dendritic cells were able to bind B. infantis at a high frequency, while CD103- dendritic 
cells bound B. infantis at a low frequency (Figure 2b and Supplementary figure 1). 
Moreover, CD103+ dendritic cells gene expression of the retinoic acid metabolizing 
enzymes ALDH1a1 and ALDH1a2 were significantly upregulated following co-
incubation with B. infantis (Figure 2d).  In addition, CD103+ and CD103- dendritic cells 
were isolated from the mucosa by flow cytometric sorting and were co-incubated with 
B. infantis.  Gene expression for ALDH1a1 and ALDH1a2 was significantly increased 
following B. infantis co-incubation only in CD103+ dendritic cells, but not CD103- 
dendritic cells (Figure 2e). 
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Figure 2. CD103+RALDH+ dendritic cells are elevated in the LP following B. infantis feeding. 
Flow cytometric assessment of LP and MLN revealed that B. infantis feeding is associated with 
increased CD103+RALDH+ dendritic cells within the LP (n=7), compared to the control group (n=8), 
analysed using unpaired student t-tests (a). Citral blocked the increase in LP CD103+RALDH+ dendritic 
cells (n=7). (b) Multispectral flow cytometry imaging identified CD103+ dendritic cells that efficiently 
bind CFSE-labelled B. infantis. (c) Flow cytometric analysis of CD11c+MHCII+CD103+ dendritic cells 
from the mucosa demonstrated that approximately 38% of CD103+ dendritic cells bound B. infantis. 
Isolated mucosal CD11c+ dendritic cells upregulate mRNA for RALDH enzymes following in vitro 
incubation with B. infantis (d), while the increase in gene expression is specific to CD103+ dendritic cells 
(e).  
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B. infantis suppression of TH17 cells is retinoic acid-dependent 
Ileal LP single cell suspensions were examined for IL-17, IFN-γ and IL-4 
positive lymphocytes.  The percentage of IL-17+ lymphocytes within the LP was 
significantly reduced following B. infantis feeding for 7 days, while the reduction in 
IFN-γ+ lymphocytes approached statistical significance (Figure 3a). Citral treatment 
reversed the B. infantis suppression of IL-17+ and IFN-γ+ lymphocytes within the LP.  
Neither B. infantis feeding nor citral treatment altered the percentage of IL-4+ 
lymphocytes within the LP (Figure 3a).  Isolated LP cells were cultured in vitro for 
24 hours and spontaneous secretion of TH17 polarizing cytokines were measured in 
culture supernatants. Both IL-1β and IL-6 secretion were significantly reduced by B. 
infantis feeding. Citral reversed the suppression of IL-1β secretion and partially 
reversed the suppression of IL-6 secretion (Figure 3b).  One potential explanation for 
the B. infantis suppression of TH17 cells within the LP is that B. infantis may alter 
lymphocyte recruitment to the LP. Expression of the intergrin α4β7 and the chemokine 
receptor CCR9 influence the gut homing of lymphocytes. Both α4β7+ and CCR9+ 
lymphocytes populations were significantly suppressed following B. infantis feeding 
(Figure 3c). However, citral treatment had no effect on the B. infantis suppression 
of α4β7+ lymphocytes, with a minor effect on CCR9+ lymphocytes, suggesting that the 
B. infantis effect on lymphocyte homing is independent of retinoic acid metabolism. 
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Figure 3. B. infantis alters lymphocyte phenotypes within the LP. 
(a) IL-17+ lymphocytes were significantly reduced and IFN-γ+ cells were substantially reduced 
within the LP of B. infantis-fed mice (n=8), compared to the control group (n=6), an effect that was 
blocked by citral (n=5). No effect was observed for IL-4+ lymphocytes. (b) Isolated LP was cultured in 
vitro and cytokine secretion measured after 24 hours.  B. infantis feeding reduced the in vitro secretion of 
the TH17-polarising cytokines IL-1β and IL-6, which was partially reversed by citral. (c) B. infantis 
feeding was associated with a decrease in the proportion of LP lymphocytes expressing the gut homing 
receptors α4β and CCR9.  Citral did not reverse the decrease in α4β7+ lymphocytes and had a minor 
influence on CCR9+ lymphocytes. Statisical significance was estimated using unpaired student t-tests. 
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B. infantis induction of Foxp3+ lymphocytes is retinoic acid-independent 
As previously described, B. infantis feeding was associated with increased 
numbers of regulatory lymphocytes within the mucosa (Figure 4a).  Foxp3+ 
T lymphocytes were increased within the LP and showed a tendency to be increased for 
MLN (Figure 4b). However, citral did not attenuate the increase in Foxp3+ lymphocytes 
suggesting that mechanisms other than retinoic acid metabolism can be responsible for 
this effect.  IL-10+ CD4+lymphocytes were significantly increased in the MLN, but not 
the LP of B. infantis-fed animals, which was blocked by citral (Figure 4c). 
 
 
96 
 
Results 
 
Figure 4. B. infantis induction of Foxp3+ lymphocytes is not RALDH-dependent. 
(a) Representative flow cytometric dot-plots are illustrated for CD4 and Foxp3 populations 
within MLN and LP. (b) The increase in CD4+Foxp3+ T lymphocytes following B. infantis feeding in the 
LP (n=6) is not reversed by citral treatment (n=5). (c) CD4+IL-10+ T lymphocytes increased within MLN 
(n=8), but not the LP (n=7). LP statistical significance was estimated using the non-parametric Mann-
Whitney test, while MLN statistics were determined using the parametric unpaired student t-test. 
 
 
 
B. infantis attenuation of colitis is retinoic acid-dependent 
In the DSS model of colitis, B. infantis feeding was associated with decreased 
histopathology (Figure 5a and 5b) and decreased MPO levels (Figure 5c).  Citral 
treatment blocked the protective effect of B. infantis feeding. Citral itself did not impact 
the severity of DSS-induced colitis (Figure 5a) or LP TH1 and TH17 subsets (Figure 6a). 
However, B. infantis significantly reduced the numbers of IL-17+ and IFN-γ+ 
lymphocytes within the LP of colitic animals, which was blocked by citral treatment 
(Figure 6a).  The proportion of Foxp3+ lymphocytes within the MLN increased 
significantly due to the induction of colitis and B. infantis feeding had no effect on the 
increase in Foxp3+ lymphocytes within the MLN (Figure 6b). In contrast, DSS-induced 
colitis was associated with a significantly reduced percentage of Foxp3+ lymphocytes 
within the LP and B. infantis feeding partially reversed the drop in Foxp3+ lymphocytes 
within the LP (Figure 6b).  As described above, B. infantis feeding to healthy animals 
significantly reduced α4β7+ and CCR9+ lymphocytes within the LP, however B. infantis 
feeding to animals with DSS-induced colitis did not alter α4β7+ or CCR9+ lymphocyte 
numbers (Figure 6c).  Colitis was associated with significantly increased numbers of 
CD103+ dendritic cells within the LP (Figure 7a).  However, the percentage of CD103+ 
dendritic cells that were RALDH+ were significantly reduced in the control DSS group, 
while B. infantis feeding reversed the suppression of RALDH+ CD103+ dendritic cells 
(Figure 7b). Moreover, the frequency of CD11c+ CD103-RALDH+ cells was reduced in 
the inflamed LP and B. infantis feeding did not affect retinoic acid production by 
CD103- cells (Figure 7c). The upregulation of CD103 in the colitis group was primarily 
seen on CD11c+CD11b+ dendritic cells, while the upregulation of CD103 in the 
B. infantis group was within the CD11c+CD11b- dendritic cell subpopulation (Figure 
7d). 
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Figure 5. DSS-induced colitis is reduced by B. infantis feeding. 
Four murine study groups were examined – Untreated (no DSS and no B. infantis), Control (DSS 
alone), B. infantis (DSS and B. infantis), citral (DSS and citral) and B. infantis & citral (DSS, B. infantis 
and citral).   (a) The histopathology inflammatory score was significantly reduced by B. infantis feeding 
(n=5), but not when citral was co-administered (n=8). Citral administered with DSS did not increase 
inflammation in the colon in comparison to DSS alone (n=7). (b) Representative slides of the murine gut 
are illustrated. (c) Colonic myeloperoxidase (MPO) levels were reduced in B. infantis-fed mice, which 
was not observed with B. infantis and citral treatment.  Statistical significance was determined using non-
parametric Mann-Whitney tests. 
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Figure 6. B. infantis alters T cell phenotypes within the inflamed LP. 
(a) DSS colitis increases the proportion of IL-17+ and IFN-γ+ CD4 T lymphocytes within the LP 
(n=8). However, B. infantis feeding (n=6) significantly reduces LP IL-17+ and IFN-γ+ subpopulations 
compared to DSS alone, which was inhibited by citral (n=7). Both subpopulations were similarly 
increased in DSS alone and DSS & citral (n=7).  (b) CD4+Foxp3+ lymphocytes were significantly 
increased in the MLN during DSS colitis (n=6), with a significant decrease of Foxp3+ lymphocytes being 
observed within the LP (n=6).  B. infantis feeding (n=6) did not alter the increase in Foxp3+ cells in the 
MLN, but partially restored the deficit in Foxp3+ cells within the LP (n=6). (c) Expression of the gut 
homing receptors α4β7 and CCR9 did not significantly change for any of the groups examined.  
Statistical significance was determined using unpaired student t-tests. 
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Figure 7. B. infantis suppresses the expansion of a pro-inflammatory dendritic cell phenotype 
within the LP. 
Untreated (n=8), DSS colitis (n=7), DSS and B. infantis treated (n=6) and DSS, B. infantis and 
citral treated animals (n=7) were compared for dendritic cell subsets within the LP. (a) The proportion of 
CD103+ dendritic cells within the LP was increased for all groups with DSS-induced colitis. (b) However, 
the CD103+ cells expressing RALDH was significantly reduced in the inflamed LP, which was 
normalized by B. infantis feeding. (c) The CD11c+CD103-RALDH+  cell numbers were reduced in the 
control DSS group and B. infantis did not reverse this suppression. (d) The increase in CD103+ dendritic 
cells in the inflamed LP primarily consists of CD11b+CD103+ dendritic cells, while B. infantis feeding 
was associated with an increase in CD11b-CD103+ dendritic cells.  Statistical significance for (a), (b) and 
(c) was estimated using the non-parametric Mann-Whitney test, while (d) statistics were determined using 
the parametric unpaired student t-test. 
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DISCUSSION 
In this study, we show that B. infantis is sampled by mucosal dendritic cells 
within the LP and PP, resulting in increased numbers of LP CD103+RALDH+ dendritic 
cells with tolerogenic properties.  The suppression of TH1 and TH17 lymphocytes within 
the LP was observed in the healthy and inflamed gut, which was dependent on retinoic 
acid metabolism as citral administration blocked this activity. In addition, disease 
severity was reduced by B. infantis feeding during DSS-induced colitis, which was also 
blocked by citral.  Interestingly the elevation in mucosal LP Foxp3 lymphocytes, but not 
MLN IL-10+ lymphocytes, associated with B. infantis feeding was RALDH-
independent. 
LP CD103+ dendritic cells are derived from circulating common dendritic cell 
precursors (not from LP CD103- intermediates), require Flt3 ligand for their 
development and migrate efficiently to the draining lymph nodes 22, 23.  However, the 
microbial factors that influence the tolerogenic potency of CD103+ dendritic cells 
within the LP are only beginning to be elucidated. One study using germ-free animals 
suggested that CD103+ dendritic cells within the colon did not require the presence of a 
microbiota 24. In contrast, another study recently demonstrated that Bifidobacterium 
breve promoted development of IL-10-producing Tr1 cells in the colon by intestinal 
CD103+ dendritic cells via the TLR2/MyD88-dependent induction of IL-27 and IL-10 
25.  We have also previously demonstrated in vitro that B. infantis-induced IL-10 
secretion by human myeloid dendritic cells was TLR2-dependent 21.  However, Jeon et 
al did not detect alterations in TH17 or TH1 populations within the colon following 
B. breve feeding 25.  As they did not measure CD103+RALDH activity, direct 
comparisons with the present study are not possible but it’s clear that the B. infantis-
associated suppression of TH17 and TH1 cells is dependent on RALDH activity. 
Intestinal homeostasis is maintained by regulatory T cell populations consisting 
of two major CD4+ T cell subsets, Foxp3+ Treg cells and IL-10-producing Tr1 cells 26. 
Site-specific alterations in regulatory lymphocyte subsets are evident in this study. 
Within the LP, B. infantis increased the proportion of Foxp3+ lymphocytes, while Tr1 
cells were increased only within the MLN.  Alternative mechanisms also are required 
for induction of the two regulatory populations as citral blocked the induction of MLN 
Tr1 cells, but not the elevation in Foxp3+ cells within the LP.  Suppression of TH1 and 
TH17 lymphocytes within the LP was abrogated by citral confirming that citral 
administration did have an effect within the LP. Thus, the B. infantis induction of 
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Foxp3+ lymphocytes within the LP involves mechanisms other than retinoic acid 
metabolism.  Similarly, B. infantis reduced the proportion of α4β7 and CCR9 
lymphocytes within the LP, which was not dramatically influenced by citral.  Retinoic 
acid has been previously described to upregulate expression of gut homing receptors, 
which was not observed in our studies. This finding further supports the existence of 
additional non-RALDH-dependent mechanisms which are induced by B. infantis within 
the LP 27. 
Even though RALDH and non-RALDH mechanisms may be required for B. 
infantis-associated immunoregulatory activity within the mucosa, citral blocked the 
anti-inflammatory effect of B. infantis in the DSS colitis model confirming that the 
induction of retinoic acid metabolism is critical for the in vivo protective effects of this 
microbe.  Similar to the findings with healthy mice, B. infantis reduced TH1 and TH17 
lymphocytes within the inflamed LP, which was retinoic acid-dependent.  In contrast to 
healthy mice, B. infantis did not reduce the number of lymphocytes expressing α4β7 
and CCR9 within the inflamed LP.  While certain therapeutic approaches have focused 
on blocking gut homing receptors for amelioration of colitis, it has also been shown that 
CCR9 deficiency exacerbates colitis due to impairment of Treg recruitment to the gut 28, 
29. However, our study suggests that B. infantis does not alter recruitment of α4β7 or 
CCR9 positive lymphocytes into the inflamed LP. 
During DSS-induced colitis, the relative proportion of CD11b+CD103+ dendritic 
cells was increased within the LP, while B. infantis feeding was associated with an 
increase in CD11b-CD103+ dendritic cells. The LP CD11b+CD103+ dendritic cell subset 
has been suggested to possess proinflammatory properties within the inflamed gut 11, 30. 
In addition, this dendritic cell population was shown to play key role in TH17 cell 
differentiation in vitro 31. Furthermore, CD11b+CD103+ dendritic cells express TLR5 at 
a high level, rapidly respond to flagellin stimulation resulting in IL-23 secretion and are 
very efficient in presenting antigens to CD4+ lymphocytes 12, 32, 33.  Our data suggests 
that B. infantis, even within an inflamed microenvironment, continues to induce 
regulatory CD11b-CD103+RALDH+ dendritic cells within the LP and suppresses the 
increase in the proinflammatory CD11b+CD103+ dendritic cell population. Interestingly, 
the suppression of TH17 cells within the inflamed LP of B. infantis-fed mice correlates 
with the suppression of the CD11b+CD103+ dendritic cell subset. Further investigation 
is required to determine if there is a direct connection between B. infantis associated 
suppression of CD11b+CD103+ dendritic cells and TH17 polarisation. 
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Within the mucosa, dendritic cells are integral to promoting oral tolerance and 
preventing pathological immune responses to harmless antigens.  Dendritic cells use 
signals derived from their local environment to shape regulatory and low-level immune 
responses to the commensal microbiota, which controls the microbiota without causing 
pathology.  The breakdown in dendritic cell regulatory networks is associated with 
aberrant inflammatory activity within the gut and therapeutic strategies aimed at re-
establishing dendritic cell tolerogenic tone would be of benefit to IBD, IBS and food 
allergy patients.  One such strategy is the deliberate manipulation of CD103+RALDH+ 
dendritic cells by microbes or microbial components in combination with dietary 
supplementation with vitamin A.  The murine data presented in this report strongly 
support the further evaluation of these strategies in human clinical studies. 
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SUPPLEMENTARY DATA 
 
 
Supplementary Figure 1. B. infantis is bound at a low frequency by CD11c+MHCII+CD103- 
dendritic cells. 
Flow cytometric analysis of CD11c+MHCII+CD103- dendritic cells from the mucosa 
demonstrated that approximately 10% of CD103- dendritic cells bound B. infantis. 
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8. Final discussion 
 
Mucosal immune tolerance is a dynamically developing field of immunology. 
On our mucosal surfaces we have contact with commensal microbes, pathogens and 
allergens. DCs sample this environment and shape subsequent immune responses 
creating a balance between tolerance and inflammation. Induction of Foxp3 
T regulatory cells and the molecular mechanisms involved in this process are being 
deeply investigated. 
 
B. infantis 35624 was shown to protect against inflammation in many murine 
models, such as colitis and allergic inflammation. The cellular mechanism of action 
included Foxp3 T regulatory cells but the molecular mechanisms were unknown. 
Moreover, human trials with this bacterium were performed. For instance, oral 
consumption of B. infantis led to symptoms improvement in patients with Irritable 
Bowel Syndrome (31, 32). Recently, the concept of a central tolerogenic mechanism 
driven by specific gut microbes was supported in a human trial with B. infantis. Oral 
consumption of this bacterium attenuated inflammatory markers, not only in patients 
with gut inflammation, but also in other disorders such as chronic fatigue syndrome and 
psoriasis (33). This may be explained by an increase in Foxp3+ Tregs in the peripheral 
blood, which was at least demonstrated for healthy volunteers fed with B. infantis. Tregs 
could reduce inflammation at different sites, leading to a decrease in pro-inflammatory 
cytokines, such as TNF-α in patients plasma. As IL-6 and TNF-α are positively 
correlated with C reactive protein (CRP) production, their reduction may result in 
downregulation of CRP production by the liver and adipose tissue. Moreover, induction 
of vitamin A metabolism in the gut may result in higher retinoic acid concentration in 
the plasma and subsequent anti-inflammatory effects in other tissues. 
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8.1.  B. infantis-dependent increase in Foxp3+ Treg cells 
 
In chapter 7.1 we demonstrated that oral feeding of healthy human volunteers 
with B. infantis leads to an increase in CD4+Foxp3+ T cells within peripheral blood, 
which is consistent with observations from murine models. In addition, the Foxp3 
population displayed enhanced expression of inducible T-cell costimulator (ICOS) and 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), suggesting that these cells are functional 
Tregs (263). Numbers of Foxp3+ cells in CD25+ population were increased, while no 
Foxp3 changes were observed for CD25- T cells. This effect can be related to the 
promotion of CD25 expression (264) or to stabilization and expansion of already 
existing CD4+CD25+Foxp3+ Treg cells. In a murine model of Salmonell infection, 
inflammation was attenuated by B. infantis induced Treg cells (27). NF-κB activation, 
proinflammatory cytokine secretion and tissue damage were reduced in a Treg 
dependent manner. This ability of specific microbes to induce and/or promote Treg cells 
development may be restricted for certain bacterial strains within the gut microbiota. In 
fact, studies with other bacteria: Bifidobacterium longum AH1206, Bifidobacterium 
breve AH1205 and Lactobacillus salivarius AH102 demonstrated that only AH1206 
induced Treg cells and protected against respiratory allergic inflammation (28). 
Moreover, we have shown a role for DCs in Foxp3 cells induction. In in vitro 
experiments both mDCs and pDCs, isolated from human peripheral blood, respond to 
B. infantis but via different PRRs. Foxp3 induction by mDCs and MDDCs requires 
TLR-2, DC-SIGN and retinoic acid metabolism, while pDCs require IDO activation. 
This was the first report, which suggested that a single commensal bacterial strain 
activates distinct molecular pathways in different human DC subsets, leading in to the 
same result – Foxp3 enhancement in CD4 T cells. 
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8.2.  Activation of TLR2 and DC-SIGN signaling pathways 
 
Both DC subsets: mDCs and pDCs secrete IL-10 but not IL-12 in response to 
B. infantis stimulation. Moreover, pDCs did not upregulate IFN-α gene expression, 
whereas control cells stimulated with CpG DNA expressed IFN-α.  By use of blocking 
ODNs we demonstrated that B. infantis activates TLR9 in pDCs. This suggests that 
other receptors on pDCs have to be involved in B. infantis recognition and modulate 
cytokine secretion. For instance, in case of pDCs BDCA-2 is well described as 
a receptor, which can decrease TLR9 induced IFN-α secretion (154). mDCs and 
MDDCs recognize B. infantis via TLR2 and more precisely via the TLR2/6 
heterodimer. This receptor was shown to be critical for immune response to microbes. 
TLR2-/- mice are more susceptible to DSS- induced colitis and TLR2 is involved in 
promoting Foxp3 expression in response to intestinal microbes (97, 98). In humans, 
TLR2 SNPs were associated with disease phenotype in IBS patients. Interestingly, we 
could observe two classes of IL-10 secretion in response to B. infantis. One group 
responded with very high level of IL-10 secretion, while the second group with low 
level secretion. TLR2 blockade led to a stronger decrease in IL-10 secretion in the first 
group. This effect could possibly be related to TLR2 SNPs. Moreover, TLR2 blockade 
led to increased IL-12 and TNF-α expression. However, the link between TLR2 
activation and suppression of IL-12 is unknown and could be directly or indirectly 
mediated. Tyrosine kinase Syk is recruited by TLRs upon ligand binding and mediates 
non-canonical NF-κB signaling pathway activation. This leads to IL-1β and IL-12p40 
downregulation in a RELB-dependent manner (145). Moreover, Syk can interact with 
TRAF6 during MyD88-dependent TLR signaling and decrease pro-inflammatory 
cytokine production (265). Both Syk and ERK activation can be involved in IL-10 and 
RALDH2 upregulation, which leads to retinoic acid and IL-10 production. These anti-
inflammatory factors are known to induce suppressor of cytokine signaling 3 (SOCS3) 
expression, which suppresses p38 MAPK and pro-inflammatory cytokines production, 
including IL-12, IL-6, TNF-α and IL-23 (224). Another possibility is that TLR2 via 
ERK mediates c-FOS phosphorylation and stabilization (266, 267). Subsequently, c-
FOS represses IL-12 production, while inducing IL-10 production. All these pathways 
could potentially be responsible for direct and indirect IL-12 downregulation mediated 
by TLR2 (268). Moreover, TLR2 signaling can be modulated on different levels by 
numerous miRNA. DC-SIGN was also activated on MDDCs and this receptor blockade 
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led to increased TNF-α and reduced IL-10 secretion. DC-SIGN can influence TLR 
signaling by Raf-1 activation and subsequent acetylation of phosphorylated NF-κB 
subunit p65 via histone acetyltransferases CREB-binding protein (CBP). This results in 
enhanced IL-10 secretion (269). However, intermediate steps of this pathway remain 
unknown. 
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8.3.  Retinoic acid metabolism and CD103+ DCs in the gut 
 
It is well described that retinoic acid metabolism in intestinal cells and certain 
DC subsets promotes conversion of naïve T cells into Foxp3+ Tregs (270). In in vitro 
experiments, we observed upregulation of retinoic acid metabolizing enzyme RALDH2 
in mDCs and MDDCs after stimulation with B. infantis. Activation of this metabolic 
pathway was critical for Treg induction in co-cultures with autologous CD4 
T lymphocytes. Both TLR2 and DC-SIGN activation were important for RALDH2 
upregulation and RALDH activity. TLRs regulation of retinoic acid metabolism has 
been partially described (195, 207, 223). Albeit, the signaling cascade leading to 
retinoic acid metabolism is unknown. There is no evidence suggesting how CLRs (such 
as DC-SIGN) can affect vitamin A metabolism and this topic needs further 
investigation. In contrast, bacterial stimulation of pDCs led to IDO upregulation (not 
RALDH) and use of 1MT (IDO activity inhibitor) blocked Treg development in co-
cultures with autologous CD4 T cells.  
 
Retinoic acid metabolism in the small intestine is well characterized but 
regulation by microbial stimuli is still not well described. CD103+ DCs are described as 
one of the main retinoic acid producers in the gut. They express Aldh1a2, which 
encodes the RALDH2 enzyme. In chapter 7.2 we demonstrated that B. infantis feeding 
induces retinoic acid metabolism significantly in LP CD103+ DCs. These DCs are 
derived from circulating common dendritic cell precursors, require Flt3 ligand for 
development and migrate to MLN (208, 271). They are still present in the colon of germ 
free mice (272), which suggests that the colonic population depends on factors other 
than the microbiota. In fact, retinoic acid metabolism in CD103+ DCs is increased after 
vitamin A administration and this effect is mainly present in the small intestine, where 
dietary vitamin A is easily accessible.  
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8.4.  Bacteria sampling by CD103+ DCs in the gut 
 
Sorted CD103+ DCs from MLN and PP were able to increase Aldh1a1 and 
Aldh1a2 expression after B. infantis stimulation, whereas CD103- DCs were not able to 
undergo these changes. Both CD103+ and CD103- DCs are involved in Treg priming. 
However, CD103+ have enhanced capability to produce retinoic acid in response to 
certain stimuli, such as TLR2 ligands. CD103+ DCs are more efficient in the induction 
of Foxp3 Treg differentiation than CD103- DCs and increase gut homing receptor 
expression on activated T cells (189). 38% of sorted CD103+ DCs from intestinal 
mucosa bound B. infantis in vitro. This suggests a specific role for intestinal CD103+ 
DCs in mediating B. infantis-mediated effects. There has been some controversy 
regarding the potential for DCs to sample commensal bacteria in the gut. Many groups 
have shown that pathogens, such as Salmonella are effectively sampled from the 
intestine lumen by CX3C chemokine receptor 1 (CX3CR1) or CD11c DC trans-
epithelial dendrites (273, 274) but it was not clear if the same mechanisms apply for 
commensal microbes and if CD103+ DCs are also involved in this process. To address 
this question we administered carboxyfluorescein succinimidyl ester (CFSE)-labeled 
B. infantis by oral gavage and visualized bacteria binding to DCs in the PP and LP after 
2 hours and 4 hours. We were able to show that more small intestinal LP DCs were 
CFSE positive after 4 hours, compared to 2 hours, whereas the number of PP CFSE 
DCs harboring bacteria was lower after 4 hours than after 2 hours. Recently, even more 
detailed investigation of bacteria binding by intestinal DC subsets was performed. Using 
2-photon microscopy small intestinal CD103+ DCs, expressing tight junction proteins 
Claudin-4 and ZO-2, were shown to capture bacteria via their ability to form trans-
epithelial dendrites (275). In steady-state CD103+ DCs are mainly located in murine 
LP. However, some of them patrol epithelium in the jejunum but not in the terminal 
ileum (274, 275). Some DCs are also found in the close proximity to murine colon 
epithelium but at lower level than in the murine small intestine (276). The transcytosis 
of bacteria via M cells into PP (277) seems to be more rapid and efficient than bacteria 
uptake by intestinal DCs monitoring gut lumen in steady-state. This could be a possible 
explanation for different dynamics of bacteria sampling, which we observed between 
small intestine LP and PP in our study with CFSE labeled B. infantis. It is worth 
mentioning that more CD103+ DCs forming dendrites were observed during infection 
with enterogenic pathogens, such as Salmonella typhimurium (275). In the small and 
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large intestine DCs were recruited to epithelium by chemokines secreted by epithelium 
and sentinel DC after first contact with pathogen (275, 278). However, in the small 
intestine this process was CCL-20 and CD103 independent (275), while in the colon 
CCL-5 and CCL-20 played important roles (278). Interestingly, intraepithelial CD103+ 
DCs sampling Salmonella in the murine small intestine were shown to harbor an 
additional marker CD11b (229). As CD103+CD11b+ DCs are highly pro-inflammatory, 
it opens the possibility for differential uptake of commensal and pathogenic bacteria by 
diverse CD103+ DC subsets in the lamina propria. There is not too much known about 
bacteria sampling in the human gut. However, the presence of CD103+ DCs in MLN 
was confirmed and potentially these cells can be also responsible for bacteria uptake in 
human intestine. 
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8.5.  CD11b+CD103+ DCs in the small intestine 
 
LP and MLN CD103+ RALDH+ DC numbers were increased in healthy animals 
after B. infantis feeding. This confirms that specific microbes can regulate retinoic 
metabolism in vivo. However, intestinal CD103+ DCs were shown to lose their 
tolerogenic properties in the presence of inflammatory mediators (279). This suggests 
that CD103 expression is not sufficient for identifying tolerogenic DCs under all 
conditions in the gut. Recently other markers were characterized on the surface of 
intestinal CD103+ DCs suggesting that this population can be further divided into 
smaller subsets. CD137 was proposed to be expressed by tolerogenic CD103+ DCs 
(280). In contrast, CD11b+CD103+DCs in the LP of the small intestine acquire 
proinflammatory properties under inflammatory conditions (281). They express TLR5 
at a high level (257) and rapidly respond to flagellin stimulation with IL-23 secretion 
(282). Moreover, LP CD11b+CX3CR1-CD103+ DCs are very efficient in presenting 
antigens to CD4+ lymphocytes (283). During DSS-induced colitis, the relative 
proportion of CD11b+CD103+ DCs within the LP was increased, while B. infantis 
feeding did not influence CD11b-CD103+ DC population. CD11b+CD103+ DC 
population was shown to play a key role in Th17 cell differentiation in vitro (281). 
However, their role in vivo was not fully established. In our model the connection 
between B. infantis associated CD11b+CD103+ DCs suppression and Th17 decrease in 
the gut were clearly seen. Recently IRF4 was identified as a critical regulator of this DC 
population efficient in Th17 cells priming (284). All DSS-treated groups had elevated 
numbers of CD103+ DCs but further characterization was critical. B. infantis 
administration induced regulatory CD11b-CD103+ RALDH active DCs within the LP 
and suppressed the increase in CD11b+CD103+ DCs. These CD11b-CD103+ RALDH+ 
DCs were involved in retinoic acid dependent suppression of inflammation. Taking this 
data together CD103+ DCs may be possibly divided into two differently behaving 
groups: CD11b+CD103+ DCs with strong pro-inflammatory properties and CD11b-
CD103+ DCs with anti-inflammatory properties, but this requires further investigation. 
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8.6.  B. infantis-induced suppression of Th1 and Th17 cells in the gut 
 
As the role for retinoic acid in Foxp3 Treg induction is well described, this 
lymphocyte population was analyzed in LP and MLN. Foxp3 Treg cells were increased 
in LP of healthy mice, however this effect was retinoic acid-independent. However, IL-
10 producing Tr1 lymphocytes were increased in MLN in a retinoic acid-dependent 
manner. This suggests a role for other factors in immunoregulatory effects driven by B. 
infantis. The synergistic role of retinoic acid and TGF-β is well described (215, 247). 
There is potential for a TGF-β effect on Treg cells in LP, partially supported by the 
observation that MDDCs stimulated with B. infantis were able to secrete TGF-β. (data 
unpublished) B. infantis oral administration also had effects on other CD4+ T cell 
subsets. Th1 and Th17 cells were decreased in a retinoic acid-dependent manner in 
healthy and inflamed LP. These effects on Th17 cells may be mediated indirectly as the 
Th17 cell priming environment was influenced by attenuation of IL-1β and IL-6 
secretion. Production of these cytokines by LP DCs could be potentially reduced via 
SOCS3 induction, as it was previously mentioned in the discussion. Th1 and Th17 
populations may be reduced by Treg cells, which can directly act on pro-inflammatory 
T lymphocytes or indirectly (via DCs) reduce inflammatory T subsets priming. CTLA-
4+ Tregs seems to be the most efficient for contact dependent regulation of CD80 and 
CD86 expression. Similarly, lymphocyte-activation gene 3 (LAG3) may block DC 
maturation. Treg cells secrete immunosuppressive cytokines, such as IL-10 and TGF-β 
and during division consume IL-2 required for efficient T cell proliferation. Galectin-1 
and granzyme B production and release induce effector T cell apoptosis (285). 
Interestingly, Tregs express CD39 and CD73 ectoenzymes generating adenosine from 
pericellular ATP. Adenosine binding to A2AR receptor leads to inhibition of T effector 
cells. Moreover, adenosine inhibits IL-6 production, while promoting TGF-β and Treg 
generation (286). As human pDCs were shown to produce IDO in response to 
B. infantis there is a possibility that also murine pDCs can react in similar manner. IDO 
promotes Treg development and leads to tryptophan starvation and tryptophan 
metabolite accumulation, which result in subsequent inhibition of T cell effector 
functions. 
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8.7.  Regulation of gut homing receptor expression by retinoic acid and 
other factors 
 
Retinoic acid was shown to induce gut homing receptors on activated B and 
T lymphocytes (185, 213, 230). However, B. infantis administration in healthy animals 
led to decrease in α4β7 and CCR9 expression on T cells within LP and for CCR9 this 
effect was retinoic acid dependent. Retinoic acid-induced CCR9 expression can be 
reduced in the presence of TGF-β (287), which upregulates the β7 subunit and CD103 
(288). This can result in low level of CCR9 and high level of α4β7 on Treg cells. α4β7 
Tregs can home not only to small intestine, but also to the colon and other mucosal 
sites, such as the respiratory tract and sites of inflammation, where the α4β7 ligand 
MadCAM is highly expressed. This can potentially explain why B. infantis 
administration led to the decrease in α4β7 CD4+ T lymphocytes. In contrast, retinoic 
acid-dependent reduced CCR9 expression can be due to a reduction in Th17 and Th1 
cells in the small intestine lamina propria, as Th17 lymphocytes were shown to express 
both gut homing receptors α4β7 and CCR9 at low concentrations of retinoic acid (287). 
Moreover, during DSS-induced colitis no effect on gut homing receptors expression on 
CD4+ T cells was observed. However, it is well known that CCR9 deficiency in mice 
exacerbates colitis and Treg cells gut homing is impaired (289, 290). This suggests that 
lack of gut homing receptor expression changes during colitis after B. infantis 
administration can be due to strong gut homing of pro- and anti-inflammatory CD4+ 
T cells together to the small and large intestine.  
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8.8.  Vitamin A and other dietary factors interacting with microbiota and 
immune system 
 
Retinoic acid metabolism seems to be critical for protection against DSS-
induced colitis. B. infantis has protective effects in IL-10-/- mice (30), which suggests 
that other factors induced by this bacterium are important. In healthy and inflamed LP 
Th1 and Th17 subsets are decreased in a retinoic acid-dependent manner. Moreover, 
myeloperoxidases activity and histological score are decreased only in mice fed with 
B. infantis. This effect is again retinoic acid- dependent as citral (RALDH enzymes 
inhibitor) suppressed the attenuation of inflammation. 
 
The induction of retinoic acid metabolism by B. infantis suggests a link between 
microbiota, diet, metabolism and immunoregulation. These results suggest that vitamin 
A and B. infantis can act synergistically and together contribute to improving immune 
homeostasis. There is growing evidence for the interaction between diet components, 
microbial metabolites and the immune system. Nondigestible carbohydrates may 
influence bacterial growth and are transformed by microbes into new polysaccharide 
structures regulating immune responses. Moreover, SCFA are produced by 
Bifidobacteria and Lactobacilli strains during fiber fermentation and contribute to 
immunoregulation (47). However, there are more microbial metabolites, such as long-
chain fatty acids (LCFAs) and biogenic amines, produced from dietary components 
within the gut. Sugar, antioxidants, certain short-chain carbohydrates and sodium salts 
of SCFA promote conjugated linoleic acids (CLAs), belonging to LCFAs, production 
by Bifidobacteria in the small intestine (291, 292). In addition, biogenic amines, such as 
histamine and γ-amino butyric acid (GABA), are produced by bacteria from accessible 
amino acids or from aldehydes and ketones. This suggests that specially formulated 
diets composed of microbes and dietary components can enhance immunoregulatory 
responses. In addition, precise monitoring of dietary habits during commensal microbes 
intervention studies may identify subgroups that respond better to therapy. 
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8.9.  Microbial compounds as new therapeutics 
 
It is unknown which component(s) of B. infantis is responsible for its 
immunoregulatory effects. Potentially it could be an exopolysaccharide, which is 
produced in high amounts by this bacterium. Until now polysaccharide A from 
Bacteroides was described as an immunoregulatory polysaccharide, which acted via 
TLR2 (98). However, there is also growing evidence suggesting that bacterial proteins 
are immunoregulatory, for instance in the induction of skin homing receptors (293). 
Isolating specific bacterial compounds and using them instead of the intact bacteria can 
be a promising direction for future therapeutic uses. It allows for application not limited 
to the gut and for new forms of administration.  Albeit, SNPs in PRRs, which 
predispose to certain diseases can became a critical limitation in this type of therapy. 
Mutation in the PRR may block ligand binding or lead to differential signaling pathway 
activation via the altered receptor. For instance, R753Q polymorphism in TLR2 
increases tuberculosis incidence via impaired dimerization with TLR6 and recruitment 
of MyD88 (294). The same mutation may interfere with a bacterial compound acting via 
heterodimer TLR2/6 in order to induce tolerogenic responses. 
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8.10.  Conclusion and outlook 
 
The microbiota in the gut lumen is continuously monitored by the GALT. 
Microbes are sampled by LP DC intra-epithelial dendrites or are delivered to PP 
resident DCs through M cells. Bacterial components are recognized by diverse PRRs, 
which are present on the surface, in the intracellular compartments and in the cytoplasm 
of DCs. Moreover, DCs respond to microbial metabolites produced in the gut lumen 
during fermentation processes. Bacterial activated DCs secrete diverse cytokines, 
immunomodulatory factors and interact with T and B lymphocytes, which leads to pro- 
or anti-inflammatory adaptive responses. Antigen presentation takes place locally in LP 
and after DC migration to the MLN. In addition, some DCs can stay within PP and 
prime naïve T cells. 
 
All these processes are involved in tolerance induction to non-pathogenic gut 
microbiota and in case of infection by enterogenic microbes provide pro-inflammatory 
responses and support pathogen eradication. However, sometimes the immune system 
responds to commensals in an inappropriate manner resulting in chronic inflammation. 
This can be due to disregulation on the DC level, including impaired recognition by 
mutated PRRs, secreting pro-inflammatory factors in response to commensal microbes 
and creating an environment, which supports Th1 and Th17 cell generation. Another 
possibility is related to regulatory mechanisms, such as Treg functionality, impairment 
and prolonged mucosal inflammation after infections. Moreover, dietary habits and 
antibiotics can modulate the gut microbiome and cause changes in quality and quantity 
of commensal microbes. This may favor microbes promoting mucosal inflammation. 
However, it remains unknown if changes in microbiota lead to inflammatory disorders 
or if they are a consequence of local inflammatory responses. 
 
An appropriate diet combined with specific commensal microbes administration 
could be a potential treatment of intestinal inflammation. Induction of tolerogenic 
signals and metabolites, such as retinoic acid may help to restore immune homeostasis 
in the gut, by improving anti-inflammatory innate and adaptive responses. B. infatis 
serves as very good example of a tolerogenic microbe preventing and reducing 
inflammation within the gastrointestinal tract. In this thesis we described molecular 
mechanisms leading to tolerance induction by this bacterium. B. infatis is sampled from 
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the gut lumen by DCs and enhances vitamin A metabolism in LP CD103+ DCs, leading 
to subsequent Foxp3+ Tregs generation (Figure 10). Moreover, pro-inflammatory Th1 
and Th17 populations are decreased within the LP. Human mDCs recognize B. infatis 
via TLR2 and DC-SIGN, while pDCS sense this bacterium via TLR9. Bacterial 
activated DCs produce IL-10, TGF-β, IDO and RALDH2, which leads to Tregs  
generation. 
 
Figure 10.  B. infatis immunoregulatory effects. 
 
B. infatis administration together with vitamin A may be beneficial for patients 
suffering from diverse intestinal inflammatory disorders. Moreover, recent reports about 
the positive impact on non-gut related diseases, such as psoriasis, opens the possibility 
for specific supplementation in other inflammatory conditions. Interestingly, the 
development of immunoregulatory bacterial compounds may broaden the spectrum of 
applications and could lead to new medicaments. 
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8.11. Contribution statement 
 
In the article “Bifidobacterium infantis 35624 administration induces Foxp3 
T regulatory cells in human peripheral blood: potential role for myeloid and 
plasmacytoid dendritic cells” experiments for Figures 1-3 were performed by David 
Groeger. Results for Figure S1 were prepared by Mario Ziegler and Liam O’Mahony. 
I performed other experiments (Figures 4-7 and Figures S2-S6) with help from Remo 
Frei, Ruth Ferstl and Mario Ziegler.  
For the article “Portrait of an immunoregulatory Bifidobacterium” I performed 
experiments presented in Figure 2. 
For the article “Immunomodulation by Bifidobacterium infantis 35624 in the 
murine lamina propria requires retinoic acid-dependent and independent mechanisms” 
work with live animals was done by Ruth Ferstl. Swiss role sections for Figure 5 were 
analyzed by Dirk Nehrbass. I performed all experiments with help from Ruth Ferstl, 
Remo Frei and Mario Ziegler. 
All experiments were supervised by Liam O’Mahony. 
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